CN116253748A - Substituted bicyclic heteroaryl compounds as KRAS G12D inhibitors - Google Patents
Substituted bicyclic heteroaryl compounds as KRAS G12D inhibitors Download PDFInfo
- Publication number
- CN116253748A CN116253748A CN202211152921.0A CN202211152921A CN116253748A CN 116253748 A CN116253748 A CN 116253748A CN 202211152921 A CN202211152921 A CN 202211152921A CN 116253748 A CN116253748 A CN 116253748A
- Authority
- CN
- China
- Prior art keywords
- cancer
- mmol
- reaction
- compound
- dissolved
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102200006539 rs121913529 Human genes 0.000 title claims description 28
- 239000003112 inhibitor Substances 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 135
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 31
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 18
- 201000011510 cancer Diseases 0.000 claims abstract description 11
- 238000011282 treatment Methods 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims description 42
- 239000012453 solvate Substances 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- 229940002612 prodrug Drugs 0.000 claims description 11
- 239000000651 prodrug Substances 0.000 claims description 11
- 206010025323 Lymphomas Diseases 0.000 claims description 10
- 206010009944 Colon cancer Diseases 0.000 claims description 9
- 230000001404 mediated effect Effects 0.000 claims description 9
- 229940124597 therapeutic agent Drugs 0.000 claims description 9
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 8
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 7
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 7
- 230000000155 isotopic effect Effects 0.000 claims description 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 7
- 201000002528 pancreatic cancer Diseases 0.000 claims description 7
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 7
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims description 6
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 5
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 5
- 208000021309 Germ cell tumor Diseases 0.000 claims description 4
- 206010062038 Lip neoplasm Diseases 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 210000003169 central nervous system Anatomy 0.000 claims description 4
- 239000013078 crystal Substances 0.000 claims description 4
- 208000024348 heart neoplasm Diseases 0.000 claims description 4
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 201000005962 mycosis fungoides Diseases 0.000 claims description 4
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 208000011654 childhood malignant neoplasm Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 3
- 201000006721 lip cancer Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 208000037968 sinus cancer Diseases 0.000 claims description 3
- 201000002314 small intestine cancer Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 3
- 208000030507 AIDS Diseases 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 206010061424 Anal cancer Diseases 0.000 claims description 2
- 206010003571 Astrocytoma Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006143 Brain stem glioma Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 2
- 206010007275 Carcinoid tumour Diseases 0.000 claims description 2
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 201000009047 Chordoma Diseases 0.000 claims description 2
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 206010014967 Ependymoma Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 2
- 208000017259 Extragonadal germ cell tumor Diseases 0.000 claims description 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 206010061252 Intraocular melanoma Diseases 0.000 claims description 2
- 208000009164 Islet Cell Adenoma Diseases 0.000 claims description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 claims description 2
- 208000032271 Malignant tumor of penis Diseases 0.000 claims description 2
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims description 2
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 208000010505 Nose Neoplasms Diseases 0.000 claims description 2
- 208000000160 Olfactory Esthesioneuroblastoma Diseases 0.000 claims description 2
- 206010031096 Oropharyngeal cancer Diseases 0.000 claims description 2
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061332 Paraganglion neoplasm Diseases 0.000 claims description 2
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims description 2
- 208000002471 Penile Neoplasms Diseases 0.000 claims description 2
- 206010034299 Penile cancer Diseases 0.000 claims description 2
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims description 2
- 206010034811 Pharyngeal cancer Diseases 0.000 claims description 2
- 208000007452 Plasmacytoma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 201000008183 Pulmonary blastoma Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 201000000582 Retinoblastoma Diseases 0.000 claims description 2
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims description 2
- 206010061934 Salivary gland cancer Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 208000000728 Thymus Neoplasms Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 201000005969 Uveal melanoma Diseases 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 206010047741 Vulval cancer Diseases 0.000 claims description 2
- 208000002458 carcinoid tumor Diseases 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims description 2
- 201000007455 central nervous system cancer Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims description 2
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims description 2
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 claims description 2
- 201000011523 endocrine gland cancer Diseases 0.000 claims description 2
- 208000024519 eye neoplasm Diseases 0.000 claims description 2
- 208000018212 fibroblastic neoplasm Diseases 0.000 claims description 2
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 201000006866 hypopharynx cancer Diseases 0.000 claims description 2
- 230000000366 juvenile effect Effects 0.000 claims description 2
- 208000006178 malignant mesothelioma Diseases 0.000 claims description 2
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims description 2
- 208000037970 metastatic squamous neck cancer Diseases 0.000 claims description 2
- 201000006462 myelodysplastic/myeloproliferative neoplasm Diseases 0.000 claims description 2
- 210000000537 nasal bone Anatomy 0.000 claims description 2
- 208000037830 nasal cancer Diseases 0.000 claims description 2
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims description 2
- 201000002575 ocular melanoma Diseases 0.000 claims description 2
- 201000006958 oropharynx cancer Diseases 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 claims description 2
- 208000021010 pancreatic neuroendocrine tumor Diseases 0.000 claims description 2
- 208000003154 papilloma Diseases 0.000 claims description 2
- 208000007312 paraganglioma Diseases 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 208000008732 thymoma Diseases 0.000 claims description 2
- 201000009377 thymus cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 210000000626 ureter Anatomy 0.000 claims description 2
- 208000037965 uterine sarcoma Diseases 0.000 claims description 2
- 206010046885 vaginal cancer Diseases 0.000 claims description 2
- 208000013139 vaginal neoplasm Diseases 0.000 claims description 2
- 201000005102 vulva cancer Diseases 0.000 claims description 2
- 201000010235 heart cancer Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 claims 1
- 208000007860 Anus Neoplasms Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000009458 Carcinoma in Situ Diseases 0.000 claims 1
- 208000009798 Craniopharyngioma Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010021042 Hypopharyngeal cancer Diseases 0.000 claims 1
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 claims 1
- 208000033383 Neuroendocrine tumor of pancreas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010067517 Pancreatic neuroendocrine tumour Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006593 Urologic Neoplasms Diseases 0.000 claims 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 1
- 201000011165 anus cancer Diseases 0.000 claims 1
- 208000021780 appendiceal neoplasm Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 201000004933 in situ carcinoma Diseases 0.000 claims 1
- 201000002529 islet cell tumor Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000008106 ocular cancer Diseases 0.000 claims 1
- 201000008859 olfactory neuroblastoma Diseases 0.000 claims 1
- 208000010639 renal pelvis urothelial carcinoma Diseases 0.000 claims 1
- 201000000334 ureter transitional cell carcinoma Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- -1 bicyclic heteroaryl compound Chemical class 0.000 abstract description 18
- 229940126204 KRAS G12D inhibitor Drugs 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 257
- 238000006243 chemical reaction Methods 0.000 description 205
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 161
- 239000000543 intermediate Substances 0.000 description 152
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 124
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 110
- 239000000243 solution Substances 0.000 description 107
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 89
- 235000019439 ethyl acetate Nutrition 0.000 description 87
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 80
- 229910052757 nitrogen Inorganic materials 0.000 description 62
- 239000007787 solid Substances 0.000 description 61
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 51
- 239000002904 solvent Substances 0.000 description 46
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 44
- 239000005457 ice water Substances 0.000 description 39
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 34
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 33
- 239000012043 crude product Substances 0.000 description 31
- 238000003818 flash chromatography Methods 0.000 description 30
- 238000000605 extraction Methods 0.000 description 29
- 238000003756 stirring Methods 0.000 description 27
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 26
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 24
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 24
- 239000004698 Polyethylene Substances 0.000 description 21
- 230000015572 biosynthetic process Effects 0.000 description 21
- 238000004440 column chromatography Methods 0.000 description 21
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 20
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 20
- 238000001035 drying Methods 0.000 description 20
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 20
- 239000003208 petroleum Substances 0.000 description 19
- 238000003786 synthesis reaction Methods 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 17
- 239000011259 mixed solution Substances 0.000 description 17
- 239000011541 reaction mixture Substances 0.000 description 17
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000000460 chlorine Chemical group 0.000 description 15
- 238000010438 heat treatment Methods 0.000 description 15
- 238000001802 infusion Methods 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 14
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 14
- 229910000024 caesium carbonate Inorganic materials 0.000 description 14
- 235000002639 sodium chloride Nutrition 0.000 description 13
- SCLLZBIBSFTLIN-IFMUVJFISA-N C1=C(C=C(C2=C1C=CC(F)=C2C#C)C1=NC=C2C(N3CC4NC(CC4)C3)=NC(=NC2=C1F)OC[C@@]12C[C@H](CN2CCC1)F)O Chemical compound C1=C(C=C(C2=C1C=CC(F)=C2C#C)C1=NC=C2C(N3CC4NC(CC4)C3)=NC(=NC2=C1F)OC[C@@]12C[C@H](CN2CCC1)F)O SCLLZBIBSFTLIN-IFMUVJFISA-N 0.000 description 12
- 230000035772 mutation Effects 0.000 description 12
- 239000002994 raw material Substances 0.000 description 12
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 12
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 11
- 229940126203 MRTX1133 Drugs 0.000 description 11
- 239000012295 chemical reaction liquid Substances 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 230000001105 regulatory effect Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 238000004809 thin layer chromatography Methods 0.000 description 10
- 238000005406 washing Methods 0.000 description 10
- 102100030708 GTPase KRas Human genes 0.000 description 9
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 9
- 239000012074 organic phase Substances 0.000 description 9
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 9
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- 238000001990 intravenous administration Methods 0.000 description 8
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 239000012230 colorless oil Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 229920000858 Cyclodextrin Polymers 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 102200006538 rs121913530 Human genes 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 229910000104 sodium hydride Inorganic materials 0.000 description 6
- 102100039856 Histone H1.1 Human genes 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 239000012280 lithium aluminium hydride Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 230000001028 anti-proliverative effect Effects 0.000 description 4
- 229960004853 betadex Drugs 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- KQIADDMXRMTWHZ-UHFFFAOYSA-N chloro-tri(propan-2-yl)silane Chemical compound CC(C)[Si](Cl)(C(C)C)C(C)C KQIADDMXRMTWHZ-UHFFFAOYSA-N 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- 235000011056 potassium acetate Nutrition 0.000 description 4
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000010791 quenching Methods 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 238000000967 suction filtration Methods 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 4
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 3
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 101710192082 Histone H1.1 Proteins 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 210000001853 liver microsome Anatomy 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 238000004237 preparative chromatography Methods 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- NXQKSXLFSAEQCZ-SFHVURJKSA-N sotorasib Chemical compound FC1=CC2=C(N(C(N=C2N2[C@H](CN(CC2)C(C=C)=O)C)=O)C=2C(=NC=CC=2C)C(C)C)N=C1C1=C(C=CC=C1O)F NXQKSXLFSAEQCZ-SFHVURJKSA-N 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 3
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- PEMUGDMSUDYLHU-ZEQRLZLVSA-N 2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile Chemical compound ClC=1C=CC=C2C=CC=C(C=12)N1CC=2N=C(N=C(C=2CC1)N1C[C@@H](N(CC1)C(C(=C)F)=O)CC#N)OC[C@H]1N(CCC1)C PEMUGDMSUDYLHU-ZEQRLZLVSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- MSHFRERJPWKJFX-UHFFFAOYSA-N 4-Methoxybenzyl alcohol Chemical compound COC1=CC=C(CO)C=C1 MSHFRERJPWKJFX-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 238000011729 BALB/c nude mouse Methods 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 239000001116 FEMA 4028 Substances 0.000 description 2
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 2
- 102100029974 GTPase HRas Human genes 0.000 description 2
- 102100039788 GTPase NRas Human genes 0.000 description 2
- 108091006109 GTPases Proteins 0.000 description 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 2
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 2
- 101001035402 Homo sapiens Histone H1.1 Proteins 0.000 description 2
- 206010069755 K-ras gene mutation Diseases 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 101150040459 RAS gene Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- RYXZOQOZERSHHQ-UHFFFAOYSA-N [2-(2-diphenylphosphanylphenoxy)phenyl]-diphenylphosphane Chemical compound C=1C=CC=C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)C=1OC1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RYXZOQOZERSHHQ-UHFFFAOYSA-N 0.000 description 2
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 229940124988 adagrasib Drugs 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000003810 ethyl acetate extraction Methods 0.000 description 2
- HBNYJWAFDZLWRS-UHFFFAOYSA-N ethyl isothiocyanate Chemical compound CCN=C=S HBNYJWAFDZLWRS-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- IZDROVVXIHRYMH-UHFFFAOYSA-N methanesulfonic anhydride Chemical compound CS(=O)(=O)OS(C)(=O)=O IZDROVVXIHRYMH-UHFFFAOYSA-N 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 231100000590 oncogenic Toxicity 0.000 description 2
- 230000002246 oncogenic effect Effects 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 102000016914 ras Proteins Human genes 0.000 description 2
- 108010014186 ras Proteins Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 238000009210 therapy by ultrasound Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- RCBGOJFTPHCJDB-DMTCNVIQSA-N (3S,4R)-4-fluoropyrrolidin-3-ol Chemical compound O[C@H]1CNC[C@H]1F RCBGOJFTPHCJDB-DMTCNVIQSA-N 0.000 description 1
- MICMHFIQSAMEJG-UHFFFAOYSA-N 1-bromopyrrolidine-2,5-dione Chemical compound BrN1C(=O)CCC1=O.BrN1C(=O)CCC1=O MICMHFIQSAMEJG-UHFFFAOYSA-N 0.000 description 1
- IZYOHLOUZVEIOS-UHFFFAOYSA-N 1-methoxycarbonylcyclopropane-1-carboxylic acid Chemical compound COC(=O)C1(C(O)=O)CC1 IZYOHLOUZVEIOS-UHFFFAOYSA-N 0.000 description 1
- JYZQJYHHWAITJQ-UHFFFAOYSA-N 1-methyl-4-propan-2-ylbenzene;ruthenium(2+) Chemical compound [Ru+2].CC(C)C1=CC=C(C)C=C1 JYZQJYHHWAITJQ-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- IKKUKDZKIIIKJK-UHFFFAOYSA-N 2,2-diethoxyethanol Chemical compound CCOC(CO)OCC IKKUKDZKIIIKJK-UHFFFAOYSA-N 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- JYWKEVKEKOTYEX-UHFFFAOYSA-N 2,6-dibromo-4-chloroiminocyclohexa-2,5-dien-1-one Chemical compound ClN=C1C=C(Br)C(=O)C(Br)=C1 JYWKEVKEKOTYEX-UHFFFAOYSA-N 0.000 description 1
- MGKPFALCNDRSQD-UHFFFAOYSA-N 2-(4-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C(F)C=C1 MGKPFALCNDRSQD-UHFFFAOYSA-N 0.000 description 1
- FBPINGSGHKXIQA-UHFFFAOYSA-N 2-amino-3-(2-carboxyethylsulfanyl)propanoic acid Chemical compound OC(=O)C(N)CSCCC(O)=O FBPINGSGHKXIQA-UHFFFAOYSA-N 0.000 description 1
- SFRJQFICUQFDFU-UHFFFAOYSA-N 2-amino-4-bromo-3-fluorobenzoic acid Chemical compound NC1=C(F)C(Br)=CC=C1C(O)=O SFRJQFICUQFDFU-UHFFFAOYSA-N 0.000 description 1
- HNNUBQWDWJNURV-UHFFFAOYSA-N 2-bromoethynyl-tri(propan-2-yl)silane Chemical compound CC(C)[Si](C(C)C)(C(C)C)C#CBr HNNUBQWDWJNURV-UHFFFAOYSA-N 0.000 description 1
- SDTMFDGELKWGFT-UHFFFAOYSA-N 2-methylpropan-2-olate Chemical compound CC(C)(C)[O-] SDTMFDGELKWGFT-UHFFFAOYSA-N 0.000 description 1
- RKATWUBDSJHPEV-UHFFFAOYSA-N 3,3-difluorocyclobutan-1-amine Chemical compound NC1CC(F)(F)C1 RKATWUBDSJHPEV-UHFFFAOYSA-N 0.000 description 1
- JHUUPUMBZGWODW-UHFFFAOYSA-N 3,6-dihydro-1,2-dioxine Chemical compound C1OOCC=C1 JHUUPUMBZGWODW-UHFFFAOYSA-N 0.000 description 1
- LZPWAYBEOJRFAX-UHFFFAOYSA-N 4,4,5,5-tetramethyl-1,3,2$l^{2}-dioxaborolane Chemical compound CC1(C)O[B]OC1(C)C LZPWAYBEOJRFAX-UHFFFAOYSA-N 0.000 description 1
- AXDJCCTWPBKUKL-UHFFFAOYSA-N 4-[(4-aminophenyl)-(4-imino-3-methylcyclohexa-2,5-dien-1-ylidene)methyl]aniline;hydron;chloride Chemical compound Cl.C1=CC(=N)C(C)=CC1=C(C=1C=CC(N)=CC=1)C1=CC=C(N)C=C1 AXDJCCTWPBKUKL-UHFFFAOYSA-N 0.000 description 1
- TZHQWUAOIWRFSW-UHFFFAOYSA-N 4-bromo-2,6-difluorobenzonitrile Chemical compound FC1=CC(Br)=CC(F)=C1C#N TZHQWUAOIWRFSW-UHFFFAOYSA-N 0.000 description 1
- YRLGBXZZABNBNL-UHFFFAOYSA-N 4-bromo-2-fluoro-3-methylpyridine Chemical compound CC1=C(Br)C=CN=C1F YRLGBXZZABNBNL-UHFFFAOYSA-N 0.000 description 1
- LAVPYRPTHABUAD-UHFFFAOYSA-N 6-bromo-2,3-difluorobenzaldehyde Chemical compound FC1=CC=C(Br)C(C=O)=C1F LAVPYRPTHABUAD-UHFFFAOYSA-N 0.000 description 1
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 101100404726 Arabidopsis thaliana NHX7 gene Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 240000008213 Brosimum alicastrum Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 102100039855 Histone H1.2 Human genes 0.000 description 1
- 101001035375 Homo sapiens Histone H1.2 Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- MFESCIUQSIBMSM-UHFFFAOYSA-N I-BCP Chemical compound ClCCCBr MFESCIUQSIBMSM-UHFFFAOYSA-N 0.000 description 1
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 1
- 229940124785 KRAS inhibitor Drugs 0.000 description 1
- 101150105104 Kras gene Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 206010073099 Lobular breast carcinoma in situ Diseases 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000006833 Multifunctional Enzymes Human genes 0.000 description 1
- 108010047290 Multifunctional Enzymes Proteins 0.000 description 1
- 101100523539 Mus musculus Raf1 gene Proteins 0.000 description 1
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Substances BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102000057028 SOS1 Human genes 0.000 description 1
- 108700022176 SOS1 Proteins 0.000 description 1
- 101100197320 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) RPL35A gene Proteins 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 101150100839 Sos1 gene Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 239000012391 XPhos Pd G2 Substances 0.000 description 1
- QSGREIXRTDCBHO-UHFFFAOYSA-N [3-(hydroxymethyl)oxetan-3-yl]methanol Chemical compound OCC1(CO)COC1 QSGREIXRTDCBHO-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 201000007538 anal carcinoma Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 201000004571 bone carcinoma Diseases 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 201000010983 breast ductal carcinoma Diseases 0.000 description 1
- KXVUSQIDCZRUKF-UHFFFAOYSA-N bromocyclobutane Chemical compound BrC1CCC1 KXVUSQIDCZRUKF-UHFFFAOYSA-N 0.000 description 1
- LKXYJYDRLBPHRS-UHFFFAOYSA-N bromocyclopropane Chemical compound BrC1CC1 LKXYJYDRLBPHRS-UHFFFAOYSA-N 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052801 chlorine Chemical group 0.000 description 1
- RSLSVURFMXHEEU-UHFFFAOYSA-M chloropalladium(1+);dicyclohexyl-[3-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane;2-phenylaniline Chemical compound [Pd+]Cl.NC1=CC=CC=C1C1=CC=CC=[C-]1.CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC(P(C2CCCCC2)C2CCCCC2)=C1 RSLSVURFMXHEEU-UHFFFAOYSA-M 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 208000014921 colon small cell neuroendocrine carcinoma Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- LBJNMUFDOHXDFG-UHFFFAOYSA-N copper;hydrate Chemical compound O.[Cu].[Cu] LBJNMUFDOHXDFG-UHFFFAOYSA-N 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- USLKCMBGQFYUFI-UHFFFAOYSA-N dichloromethane;tribromoborane Chemical compound ClCCl.BrB(Br)Br USLKCMBGQFYUFI-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 1
- GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000011737 fluorine Chemical group 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 150000004687 hexahydrates Chemical class 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 150000002431 hydrogen Chemical group 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- XNXVOSBNFZWHBV-UHFFFAOYSA-N hydron;o-methylhydroxylamine;chloride Chemical compound Cl.CON XNXVOSBNFZWHBV-UHFFFAOYSA-N 0.000 description 1
- 239000008309 hydrophilic cream Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007916 intrasternal administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
- 229940012189 methyl orange Drugs 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 230000005693 optoelectronics Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000001301 oxygen Chemical group 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Chemical group 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- JQRYUMGHOUYJFW-UHFFFAOYSA-N pyridine;trihydrobromide Chemical compound [Br-].[Br-].[Br-].C1=CC=[NH+]C=C1.C1=CC=[NH+]C=C1.C1=CC=[NH+]C=C1 JQRYUMGHOUYJFW-UHFFFAOYSA-N 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 235000005828 ramon Nutrition 0.000 description 1
- 108700042226 ras Genes Proteins 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000012363 selectfluor Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- RMBAVIFYHOYIFM-UHFFFAOYSA-M sodium methanethiolate Chemical compound [Na+].[S-]C RMBAVIFYHOYIFM-UHFFFAOYSA-M 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 229940073531 sotorasib Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000004964 sulfoalkyl group Chemical group 0.000 description 1
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- VPAYJEUHKVESSD-UHFFFAOYSA-N trifluoroiodomethane Chemical compound FC(F)(F)I VPAYJEUHKVESSD-UHFFFAOYSA-N 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides a substituted bicyclic heteroaryl compound as a KRAS G12D inhibitor. The invention also provides pharmaceutical compositions comprising the compounds and their use in the treatment of cancer.
Description
Technical Field
The invention belongs to the field of medicines, and particularly relates to a substituted bicyclic heteroaryl compound which can be used as a KRAS G12D inhibitor.
Background
The human RAS gene family comprises 3 classes of RAS genes KRAS, NRAS and HRAS, encoding four different RAS proteins (KRAS-4 a, KRAS-4b, NRAS and HRAS). RAS proteins belong to the GTPase protein family, which is inactive when bound to GDP, but active when bound to GTP, and can lead to activation of signaling pathways such as downstream RAF-MAPK, PI3K-Akt, etc., leading to anti-apoptotic and proliferative effects of cells (Cell, 2017;170 (1): 17-33; cell,2020;183 (4): 850-859;Nat Rev Drug Discov,2020;19 (8): 533-552.). Activating mutations in the RAS gene are the most common oncogene driver in human cancers, with KRAS most frequently undergoing oncogenic activating mutations. For example, KRAS has a mutation rate of 86-96% in pancreatic cancer, 40-54% in colorectal cancer, and 27-39% in lung cancer (PNAS, 2019;116 (32): 15823-15829;Pathol Res Pract,2009;205,858-862; nature,2012;491,399-405; nature,2014;511, 543-550).
Oncogenic driving mutations can occur at various sites in the KRAS gene, most commonly at the G12 site, including G12C, G12D, G V, and these mutations can reduce the GTPase activity of the KRAS protein, thereby resulting in the KRAS protein being active for a long period of time, resulting in malignant transformation of the Cell and carcinogenesis (Cell, 2017;170 (1): 17-33;Nat Rev Drug Discov,2020;19 (8): 533-552). The frequently occurring KRAS mutation types vary among different cancer types, e.g., about 13% of lung cancer patients have G12C mutations (N Engl Med J,2021;384 (25): 2382-2393); whereas in pancreatic cancer, 33.8% of patients develop G12D mutations, but only 1.7% of patients develop G12C mutations; in colorectal Cancer, about 10-12% of patients develop G12D mutations, while the incidence of G12C mutations is less than 3% (Nat Rev Cancer 2018;18 (12): 767-777).
Unlike ATP-dependent protein kinases (affinity of proteins to ATP at the micromolar level), KRAS proteins have affinities to GDP/GTP at the picomolar level, compound molecules have difficulty competing effectively with GDP/GTP production to inhibit KRAS signaling pathways, which severely hampers the development of KRAS inhibitors (Cell, 2017;170 (1): 17-33; cell,2020;183 (4): 850-859;Nat Rev Drug Discov,2020;19 (8): 533-552). In recent years, "allosteric" binding cavities have been found on KRAS proteins that compete with non-GDP/GTP for efficient binding to small molecules, which greatly facilitate the development of targeted drugs that target KRAS mutation-driven tumors. Currently, MRTX-849 (Adagrasib) and AMG510 (Sotorasib) targeting KRAS G12C have demonstrated excellent efficacy in clinical studies (N Engl J Med.2020;383 (13): 1207-1217;Cancer Discov.2020;10 (1): 54-71), and AMG510 has been successfully marketed under FDA approval at month 5 of 2021. Drug development targeting KRAS G12D mutations is also in an early stage relative to KRAS G12C drug development; however, as indicated above, there is a very high KRAS G12D mutation rate in many tumors and the development of KRAS G12D inhibitors is of great importance.
The U.S. Mirati company reports that the KRAS G12D small molecule MRTX1133 is administrated intravenously, but the invention does not enter clinical research, and the targeting KRAS G12D small molecule drug has excellent in vivo efficacy and greater safety, so as to solve the clinical unmet needs.
Disclosure of Invention
In one aspect, the invention provides a compound, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate, or solvate thereof, wherein the compound is selected from the group consisting of:
in another aspect, the invention provides a pharmaceutical composition comprising a compound of the invention, and optionally a pharmaceutically acceptable excipient.
In another aspect, the invention provides pharmaceutical compositions comprising a compound of the invention and a pharmaceutically acceptable excipient, which also contains an additional therapeutic agent.
In another aspect, the invention provides the use of a compound of the invention in the manufacture of a medicament for the treatment and/or prophylaxis of KRAS G12D mutein mediated diseases.
In another aspect, the invention provides a method of treating and/or preventing KRAS G12D mutein-mediated diseases in a subject comprising administering to the subject a compound of the invention or a composition of the invention.
In another aspect, the invention provides a compound of the invention or a composition of the invention for use in the treatment and/or prevention of KRAS G12D mutein-mediated diseases.
In particular embodiments, the disease treated by the present invention includes a cancer selected from the group consisting of: acute myeloid leukemia, juvenile cancer, childhood adrenocortical carcinoma, AIDS-related cancers (e.g., lymphoma and kaposi's sarcoma), anal carcinoma, appendicular carcinoma, astrocytoma, atypical teratoid, basal cell carcinoma, cholangiocarcinoma, bladder carcinoma, bone carcinoma, brain stem glioma, brain tumor, breast carcinoma, bronchial tumor, burkitt lymphoma, carcinoid tumor, atypical teratoid, embryo tumor, germ cell tumor, primary lymphoma, cervical cancer, childhood cancer, chordoma, heart tumor, chronic Lymphocytic Leukemia (CLL), chronic Myelogenous Leukemia (CML), chronic myeloproliferative disorders, colon cancer, colorectal cancer, craniopharyngeal tumor, cutaneous T cell lymphoma, extrahepatic Duct Carcinoma (DCIS), embryo tumor CNS cancers, endometrial cancers, ependymomas, esophageal cancers, olfactory neuroblastomas, ewing's sarcoma, extracranial germ cell tumors, extragonadal germ cell tumors, eye cancers, skeletal fibroblastic tumors, gall bladder cancers, stomach cancers, gastrointestinal carcinoid tumors, gastrointestinal stromal tumors (GIST), germ cell tumors, gestational trophoblastoma, hairy cell leukemia, head and neck cancers, heart cancers, liver cancers, hodgkin's lymphoma, hypopharynx cancers, intraocular melanoma, islet cell tumors, pancreatic neuroendocrine tumors, kidney cancers, laryngeal cancers, lip and oral cancers, liver cancers, lobular Carcinoma In Situ (LCIS), lung cancers, lymphomas, metastatic squamous neck cancers with harboring primary foci, mesogenic cancers, oral cancers, multiple endocrine tumor syndromes, multiple myeloma/plasmacytoma, mycosis fungoides, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasms, multiple myeloma, merkel cell carcinoma, malignant mesothelioma, malignant fibrous histiocytoma and osteosarcoma of the bones, nasal and sinus cancers, nasopharyngeal carcinoma, neuroblastoma, non-hodgkin's lymphoma, non-small cell lung cancer (NSCLC), oral cancer, lip and oral cancer, oropharyngeal cancer, ovarian cancer, pancreatic cancer, papilloma, paraganglioma, sinus and nasal cancer, parathyroid cancer, penile cancer, pharyngeal cancer, pleural-lung blastoma, primary Central Nervous System (CNS) lymphoma, prostate cancer, rectal cancer, transitional cell carcinoma, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, skin cancer, gastric cancer, small cell lung cancer, small intestine cancer, soft tissue sarcoma, cell lymphoma, testicular cancer, laryngeal cancer, thymoma and thymus cancer, thyroid cancer, transitional cell carcinoma of the kidney and ureter, cell tumor, rare cancer, vaginal cancer, uterine sarcoma, vulval cancer, virus-induced cancer or cancer of the lung cancer, preferably, colorectal cancer, or non-small cell carcinoma of the colon, small intestine cancer.
Other objects and advantages of the present invention will be apparent to those skilled in the art from the detailed description, examples, and claims that follow.
Definition of the definition
The term "KRAS G12D" refers to a mutant form of a mammalian KRAS protein that contains an aspartic acid to glycine amino acid substitution at amino acid position 12.
The term "pharmaceutically acceptable salts" as used herein means those carboxylate salts, amino acid addition salts of the compounds of the invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of patients without undue toxicity, irritation, allergic response and the like commensurate with a reasonable benefit/risk ratio, and effective for their intended use, including (if possible) zwitterionic forms of the compounds of the invention.
The "subject" to be administered includes, but is not limited to: a human (i.e., male or female of any age group, e.g., pediatric subjects (e.g., infants, children, adolescents) or adult subjects (e.g., young adults, middle aged adults, or senior adults)) and/or a non-human animal, e.g., a mammal, e.g., a primate (e.g., cynomolgus monkey, rhesus monkey), cow, pig, horse, sheep, goat, rodent, cat, and/or dog. In some embodiments, the subject is a human. In some embodiments, the subject is a non-human animal. The terms "human", "patient" and "subject" are used interchangeably herein.
"disease," "disorder," and "condition" are used interchangeably herein.
In general, an "effective amount" of a compound refers to an amount sufficient to elicit a biological response of interest. As will be appreciated by those of ordinary skill in the art, the effective amount of the compounds of the present invention may vary depending on the following factors: for example, biological targets, pharmacokinetics of the compound, the disease being treated, the mode of administration, and the age health and symptoms of the subject. The effective amount includes a therapeutically effective amount and a prophylactically effective amount.
"combination" and related terms refer to the simultaneous or sequential administration of a compound of the invention and another therapeutic agent. For example, the compounds of the invention may be administered simultaneously or sequentially with other therapeutic agents in separate unit dosage forms, or simultaneously with other therapeutic agents in a single unit dosage form.
Detailed description of the preferred embodiments
Herein, "the compounds of the present invention" refers to the following compounds, pharmaceutically acceptable salts, enantiomers, diastereomers, solvates, hydrates or isotopic variants thereof, and mixtures thereof.
In one embodiment, the invention relates to a compound, or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate, or solvate thereof, wherein the compound is selected from the group consisting of:
The compounds of the invention may include one or more asymmetric centers and thus may exist in a variety of stereoisomeric forms, for example, enantiomeric and/or diastereomeric forms. For example, the compounds of the invention may be individual enantiomers, diastereomers, or geometric isomers (e.g., cis and trans isomers), or may be in the form of mixtures of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomers. The isomers may be separated from the mixtures by methods known to those skilled in the art, including: chiral High Pressure Liquid Chromatography (HPLC), formation and crystallization of chiral salts; alternatively, preferred isomers may be prepared by asymmetric synthesis.
The compounds of the invention may also exist as tautomers. Compounds that exist in different tautomeric forms, one of the compounds is not limited to any particular tautomer, but is intended to encompass all tautomeric forms.
Those skilled in the art will appreciate that the organic compound may form a complex with a solvent in or from which it reacts or from which it precipitates or crystallizes. These complexes are referred to as "solvates". When the solvent is water, the complex is referred to as a "hydrate". The present invention encompasses all solvates of the compounds of the present invention.
The term "solvate" refers to a form of a compound or salt thereof that is bound to a solvent, typically formed by a solvolysis reaction. This physical association may include hydrogen bonding. Conventional solvents include water, methanol, ethanol, acetic acid, DMSO, THF, diethyl ether, and the like. The compounds described herein may be prepared, for example, in crystalline form, and may be solvated. Suitable solvates include pharmaceutically acceptable solvates and further include stoichiometric solvates and non-stoichiometric solvates. In some cases, the solvate will be capable of isolation, for example, when one or more solvent molecules are incorporated into the crystal lattice of a crystalline solid. "solvate" includes both solvates in solution and separable solvates. Representative solvates include hydrates, ethanolates and methanolates.
The term "hydrate" refers to a compound that binds to water. Generally, the ratio of the number of water molecules contained in a hydrate of a compound to the number of molecules of the compound in the hydrate is determined. Thus, the hydrates of the compounds can be used, for example, of the formula R x H 2 O represents, wherein R is the compound, and x is a number greater than 0. A given compound may form more than one hydrate type, including, for example, monohydrate (x is 1), lower hydrate (x is a number greater than 0 and less than 1, e.g., hemihydrate (r.0.5H) 2 O)) and polyhydrates (x is a number greater than 1, e.g., dihydrate (r.2h) 2 O) and hexahydrate (R.6H) 2 O))。
The compounds of the present invention may be in amorphous or crystalline form (polymorphs). Furthermore, the compounds of the present invention may exist in one or more crystalline forms. Accordingly, the present invention includes within its scope all amorphous or crystalline forms of the compounds of the present invention. The term "polymorph" refers to a crystalline form (or salt, hydrate or solvate thereof) of a compound of a particular crystal stacking arrangement. All polymorphs have the same elemental composition. Different crystalline forms typically have different X-ray diffraction patterns, infrared spectra, melting points, densities, hardness, crystal shapes, optoelectronic properties, stability and solubility. Recrystallization solvent, crystallization rate, storage temperature, and other factors can lead to a crystalline form predominating. Various polymorphs of a compound can be prepared by crystallization under different conditions.
The invention also includes isotopically-labeled compounds (isotopically-variant) which are identical to those recited in the present invention, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine and chlorine, respectively, for example 2 H、 3 H、 13 C、 11 C、 14 C、 15 N、 18 O、 17 O、 31 P、 32 P、 35 S、 18 F and F 36 Cl. The compounds of the invention, prodrugs thereof, and pharmaceutically acceptable salts of the compounds or prodrugs thereof, which contain the isotopes described above and/or other isotopes of other atoms, are within the scope of this invention. Certain isotopically-labeled compounds of the present invention, e.g., for incorporation of a radioisotope (e.g. 3 H and 14 c) Those useful in drug and/or substrate tissue distribution assays. Tritium, i.e. tritium 3 H and carbon-14 14 The C isotopes are particularly preferred because they are easy to prepare and detect. Further, substitution by heavier isotopes, e.g. deuterium, i.e 2 H may be preferred in some cases because higher metabolic stability may provide therapeutic benefits, such as extended in vivo half-life or reduced dosage requirements. Isotopically-labeled compounds of the present invention and prodrugs thereof can generally be prepared by carrying out the schemes and/or examples and preparations described belowExamples the disclosed process replaces the non-isotopically labeled reagent with a readily available isotopically labeled reagent.
In addition, prodrugs are also included within the context of the present invention. The term "prodrug" as used herein refers to a compound that is converted in vivo by hydrolysis, e.g. in blood, into its active form having a medical effect. Pharmaceutically acceptable prodrugs are described in t.higuchi and v.stilla, prodrugs as Novel Delivery Systems, a.c. s.symposium Series vol.14, edward b.roche, ed., bioreversible Carriers in Drug Design, american Pharmaceutical Association and Pergamon Press,1987, and d.fleisher, s.ramon and h.barbra "Improved oral drug delivery: solubility limitations overcome by the use of prodrugs ", advanced Drug Delivery Reviews (1996) 19 (2) 115-130, each of which is incorporated herein by reference.
Pharmaceutical compositions and kits
In another aspect, the invention provides a pharmaceutical composition comprising a compound of the invention (also referred to as an "active ingredient") and a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical composition comprises an effective amount of a compound of the present invention. In some embodiments, the pharmaceutical composition comprises a therapeutically effective amount of a compound of the invention. In some embodiments, the pharmaceutical composition comprises a prophylactically effective amount of a compound of the present invention.
Pharmaceutically acceptable excipients for use in the present invention refer to non-toxic carriers, adjuvants or vehicles that do not destroy the pharmacological activity of the co-formulated compounds. Pharmaceutically acceptable carriers, adjuvants or vehicles that may be used in the compositions of the invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins (e.g., human serum albumin), buffer substances (e.g., phosphates), glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes (e.g., protamine sulfate), disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, silica gel, magnesium trisilicate, polyvinylpyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol, and lanolin.
The invention also includes kits (e.g., pharmaceutical packages). Kits provided can include a compound of the invention, other therapeutic agent, and first and second containers (e.g., vials, ampoules, bottles, syringes, and/or dispersible packages or other suitable containers) containing a compound of the invention, other therapeutic agent. In some embodiments, the provided kits may also optionally include a third container containing pharmaceutically acceptable excipients for diluting or suspending the compounds of the invention and/or other therapeutic agents. In some embodiments, the compounds of the invention and other therapeutic agents provided in the first and second containers are combined to form one unit dosage form.
Administration of drugs
The pharmaceutical compositions provided herein may be administered by a number of routes including, but not limited to: oral, parenteral, inhalation, topical, rectal, nasal, buccal, vaginal, by implantation or other means of administration. For example, parenteral administration as used herein includes subcutaneous administration, intradermal administration, intravenous administration, intramuscular administration, intraarticular administration, intraarterial administration, intrasynovial administration, intrasternal administration, intramuscularly administration, intralesional administration, and intracranial injection or infusion techniques, preferably by intravenous administration.
Typically, an effective amount of a compound provided herein is administered. The amount of the compound actually administered may be determined by a physician, according to the circumstances involved, including the condition being treated, the route of administration selected, the compound actually administered, the age, weight and response of the individual patient, the severity of the patient's symptoms, and the like.
When used to prevent a disorder of the present invention, a subject at risk of developing the disorder is administered a compound provided herein, typically based on physician recommendations and administered under the supervision of a physician, at a dosage level as described above. Subjects at risk for developing a particular disorder generally include subjects having a family history of the disorder, or those subjects determined by genetic testing or screening to be particularly susceptible to developing the disorder.
The pharmaceutical compositions provided herein may also be administered chronically ("chronically"). Chronic administration refers to administration of a compound or pharmaceutical composition thereof over a prolonged period of time, e.g., 3 months, 6 months, 1 year, 2 years, 3 years, 5 years, etc., or may continue administration indefinitely, e.g., for the remainder of the subject's life. In some embodiments, chronic administration is intended to provide a constant level of the compound in the blood over a prolonged period of time, e.g., within a therapeutic window.
Various methods of administration may be used to further deliver the pharmaceutical compositions of the present invention. For example, in some embodiments, the pharmaceutical composition may be administered as a bolus, e.g., in order to increase the concentration of the compound in the blood to an effective level. Bolus doses depend on the targeted systemic level of active ingredient through the body, e.g., intramuscular or subcutaneous bolus doses cause slow release of the active ingredient, whereas bolus injections delivered directly to veins (e.g., by IV intravenous drip) can be delivered more rapidly, causing the concentration of the active ingredient in the blood to rise rapidly to effective levels. In other embodiments, the pharmaceutical composition may be administered in the form of a continuous infusion, for example, by IV intravenous drip, thereby providing a steady state concentration of the active ingredient in the subject's body. Furthermore, in other embodiments, a bolus dose of the pharmaceutical composition may be administered first, followed by continuous infusion.
Oral compositions may take the form of bulk liquid solutions or suspensions or bulk powders. More typically, however, the compositions are provided in unit dosage form in order to facilitate accurate dosing. The term "unit dosage form" refers to physically discrete units suitable as unitary dosages for human patients and other mammals, each unit containing a predetermined quantity of active material suitable for producing the desired therapeutic effect in association with a suitable pharmaceutical excipient. Typical unit dosage forms include pre-filled, pre-measured ampoules or syringes of liquid compositions, or in the case of solid compositions, pills, tablets, capsules and the like. In such compositions, the compound is typically a minor component (about 0.1 to about 50 wt.%, or preferably about 1 to about 40 wt.%) with the remainder being various carriers or excipients and processing aids useful for forming the desired administration form.
For oral doses, a typical regimen is one to five oral doses per day, especially two to four oral doses, typically three oral doses. Using these modes of dosing, each dose provides from about 0.01 to about 20mg/kg of a compound of the invention, with preferred doses each providing from about 0.1 to about 10mg/kg, especially from about 1 to about 5mg/kg.
In order to provide similar blood levels to, or lower than, the use of an injected dose, a transdermal dose is typically selected in an amount of about 0.01 to about 20% by weight, preferably about 0.1 to about 10% by weight, and more preferably about 0.5 to about 15% by weight.
From about 1 to about 120 hours, especially 24 to 96 hours, the injection dosage level is in the range of about 0.1 mg/kg/hour to at least 10 mg/kg/hour. To achieve adequate steady state levels, a preloaded bolus of about 0.1mg/kg to about 10mg/kg or more may also be administered. For human patients of 40 to 80kg, the maximum total dose cannot exceed about 2 g/day.
Liquid forms suitable for oral administration may include suitable aqueous or nonaqueous carriers, buffers, suspending and dispersing agents, colorants, flavors, and the like. Solid forms may include, for example, any of the following components, or compounds having similar properties: binders, for example microcrystalline cellulose, gum tragacanth or gelatin; excipients, for example starch or lactose, disintegrants, for example alginic acid, primogel or corn starch; lubricants, for example, magnesium stearate; glidants, for example, colloidal silicon dioxide; sweeteners, for example, sucrose or saccharin; or a flavoring agent, for example, peppermint, methyl salicylate, or orange flavoring.
Injectable compositions are typically based on sterile saline or phosphate buffered saline for injectable use, or other injectable excipients known in the art. As previously mentioned, in such compositions, the active compound is typically a minor component, often about 0.05 to 10% by weight, the remainder being an injectable excipient or the like.
Transdermal compositions are typically formulated as topical ointments or creams containing the active ingredient. When formulated as ointments, the active ingredients are typically combined with a paraffinic or a water-miscible ointment base. Alternatively, the active ingredient may be formulated as a cream with, for example, an oil-in-water cream base. Such transdermal formulations are well known in the art and typically include other components for enhancing stable skin penetration of the active ingredient or formulation. All such known transdermal formulations and compositions are included within the scope provided by the present invention.
The compounds of the invention may also be administered via a transdermal device. Transdermal administration may thus be achieved using a reservoir (reservoir) or porous membrane type, or a variety of solid matrix patches.
The above components of the compositions for oral administration, injection or topical administration are merely representative. Other materials and processing techniques, etc. are set forth in Remington's Pharmaceutical Sciences,17th edition,1985,Mack Publishing Company,Easton,Pennsylvania, section 8, incorporated herein by reference.
The compounds of the present invention may also be administered in sustained release form, or from a sustained release delivery system. A description of representative sustained release materials can be found in Remington's Pharmaceutical Sciences.
The invention also relates to pharmaceutically acceptable formulations of the compounds of the invention. In one embodiment, the formulation comprises water. In another embodiment, the formulation comprises a cyclodextrin derivative. The most common cyclodextrins are α -, β -and γ -cyclodextrins consisting of 6, 7 and 8 α -1, 4-linked glucose units, respectively, optionally including one or more substituents on the linked sugar moiety, including but not limited to: methylated, hydroxyalkylated, acylated and sulfoalkyl ether substitutions. In some embodiments, the cyclodextrin is a sulfoalkyl ether β -cyclodextrin, e.g., sulfobutyl ether β -cyclodextrin, also known as Captisol. See, for example, U.S.5,376,645. In some embodiments, the formulation comprises hexapropyl- β -cyclodextrin (e.g., 10-50% in water).
Examples
The reagents employed in the present invention are commercial reagents purchased directly or synthesized by conventional methods well known in the art.
The specific reaction schemes or steps illustrated below are for use in the present invention and are as follows:
example 1
Preparation of key intermediates a1-a30
Synthesis of intermediate a1
Step 1: raw material 2-amino-3-fluoro-4-bromobenzoic acid a1-1 (15 g,64.1 mmol) was dissolved in 100mL DMF, N-chlorosuccinimide (8.56 g,64.1 mmol) was slowly added, and the reaction was stopped by heating to 80℃for 16 hours. The reaction solution was poured into 500mL of ice water, suction filtration was performed to obtain a cake, and drying was performed to obtain intermediate a1-2 (13.2 g,49.2 mmol), yield: 77%. LC-MS [ M-H ] - =267.
Step 2: to a 200mL round bottom flask was added urea (35.3 g,588 mmol) and the previous intermediate a1-2 (10.5 g,39.2 mmol), and the reaction was warmed to 200℃for 12 hours. After cooling to 80℃100mL of water was added to the system, refluxed for 10 minutes, cooled to room temperature, filtered to give a cake, washed with water, and dried in an oven to give intermediate a1-3 (4.0 g,13.7 mmol). Yield: 35%. LC-MS: [ M+H ]] + =294。
Step 3: the intermediates a1-3 (4.0 g,13.7 mmol) and N, N-diisopropylethylamine (5.3 g,41.1 mmol) of the above step were dissolved in 15mL of phosphorus oxychloride, and the reaction was stopped by heating to 120℃for 8 hours. The solvent was distilled off under reduced pressure, and column chromatography was carried out to give intermediate a1 (1.9 g,5.8 mmol). Yield: 42%. LC-MS: [ M+H ] ] + =331。
Synthesis of intermediates a2, a3, a16, a30
The steps are as follows: intermediate a1 (1.9 g,5.8 mmol) and starting 3, 8-diazabicyclo [3.2.1]Tert-butyl octane-8-carboxylate a2-1 (1.85 g,8.7 mmol) was dissolved in 20mL of methylene chloride, and N, N-diisopropylethylamine (2.3 g,17.4 mmol) was added thereto and reacted at room temperature for 8 hours. 60mL of water was added to the system, extraction was performed with methylene chloride, drying over anhydrous sodium sulfate, filtration, concentration and column chromatography were performed to obtain a pale yellow solid a2 (1.2 g,2.4 mmol). Yield: 41%. LC-MS: [ M+H ]] + =507。
Referring to the synthetic route for intermediate a2, the following intermediates were synthesized.
Synthesis of intermediates a4-a6, a8-a13
Step 1: 1- (methoxycarbonyl) cyclopropane-1-carboxylic acid a4-2 (3.0 g,20.8 mmol) was dissolved in 60mL of methylene chloride in ice bath, oxalyl chloride (10.5 g,83.3 mmol) was slowly added, and 5 drops of anhydrous DMF was added to react at 0℃for 20 minutes. The ice bath was removed, warmed to room temperature and stirring continued for 1 hour, and the solvent was distilled off under reduced pressure. The mixture was dissolved in 40mL of methylene chloride, and N, N-diisopropylethylamine (5.4 g,41.2 mmol) and tetrahydropyrrole a4-1 (1.78 g,25.0 mmol) were added and reacted at room temperature for 3 hours. The reaction was stopped, the solvent was distilled off under reduced pressure, and flash column chromatography was carried out to give intermediate a4-3 (2.6 g,13.2 mmol). Yield: 64%. LC-MS: [ M+H ] ] + =198。
Step 2: intermediate a4-3 (2.6 g,13.2 mmol) was dissolved in 30mL anhydrous tetrahydrofuran at-78deg.C and lithium aluminum hydride (26.4 mL, 1M) was slowly added. The reaction was stopped after 2 hours at room temperature. Slowly pouring 80mL of ice water into the reaction solution, decompressing and evaporating the organic solvent, extracting by ethyl acetate, drying by anhydrous sodium sulfate, filtering, concentrating, separating by flash column chromatography,intermediate a4 (900 mg,5.8 mmol) was obtained. Yield: 44%. LC-MS: [ M+H ]] + =156。
Referring to the synthetic route for intermediate a4, the following intermediates were synthesized.
Synthesis of intermediate a7
Step 1: 6-bromo-2, 3-difluorobenzaldehyde a7-1 (25 g,113 mmol) was dissolved in 250mL of methanol in an ice bath, sodium borohydride (8.54 g,226 mmol) was slowly added, and after stirring for 20 minutes, the reaction was continued at room temperature for 1 hour, and stopped. The reaction solution was slowly poured into saturated NH 4 Aqueous Cl solution, dichloromethane extraction, drying over anhydrous sodium sulfate, filtration and concentration gave a7-2 (23.9 g,107 mmol) as a white solid. Yield: 95%.
Step 2: intermediate a7-2 (23.9 g,107 mmol) and N, N-diisopropylethylamine (20.7 g,161 mmol) were dissolved in 200mL anhydrous tetrahydrofuran in an ice bath, methylsulfonic anhydride (20.5 g,118 mmol) was slowly added, after stirring for 20 minutes, the ice bath was removed and the reaction was continued at room temperature for 18 hours, stopping the reaction. The reaction solution was slowly poured into ice water, extracted with ethyl acetate, dried over anhydrous sodium sulfate, filtered and concentrated to give an oil a7-3 (19 g,63.1 mmol). Yield: 59%.
Step 3: to a solution of the above intermediate a7-3 (19 g,63.1 mmol) in 240mL of a mixed solution of ethanol and water (v/v, 6/1), potassium cyanide (4.49 g,69 mmol) was added. The reaction was stopped by reacting at reflux for 1 hour. The organic solvent was distilled off under reduced pressure, and the reaction solution was poured into a saturated sodium carbonate solution, stirred for 20 minutes, extracted with methylene chloride, concentrated, and separated by column chromatography to give intermediate a7-4 (10.4 g,44.8 mmol). Yield: 71%. LC-MS: [ M+H ]] + =233。
Step 4: under ice bath, the intermediate a7-4 (10.4 g,44.8 mmol) of the previous step was dissolved in 80mL DMF and slowly cooledPotassium tert-butoxide (5.3 g,47.2 mmol) was added and after stirring for 20 minutes the solution became red, and a solution of ethyl isothiocyanate in DMF (6.2 g,47.2mmol,5 mL) prepared beforehand was slowly added dropwise. The reaction mixture was stirred for 1 hour, and then heated to 100℃for 30 minutes. Cooled to room temperature, the reaction mixture was slowly poured into ice water to quench the reaction, filtered to give a cake, washed with n-hexane and dried in a vacuum oven to give intermediate a7-5 (13.7 g,40.0 mmol). Yield: 89%. LC-MS: [ M+H ]] + =344。
Step 5: the intermediate a7-5 (6.7 g,19.5 mmol) of the above step was dissolved in 30mL of DMSO and 30mL of aqueous sodium hydroxide (5M) was added. The reaction was stopped after 4 hours under reflux. Cooling to room temperature, slowly adding 100mL of ice water to quench the reaction, filtering to obtain a filter cake, washing with water, and drying in a vacuum drying oven to obtain a crude intermediate a7-6 (3.8 g). LC-MS: [ M+H ] ] + =272。
Step 6: the crude product of the above step a7-6 (3.8 g) and DMAP (122 mg,1 mmol) were dissolved in 30mL of a mixed solution of THF/DMF (v/v, 1/1), and Boc anhydride (4.3 g,19.5 mmol) was added. The reaction was stopped after 12 hours at room temperature. 80mL of water was added to the system, extracted with methylene chloride, dried over anhydrous sodium sulfate, filtered, and concentrated to give crude intermediate a7-7 (3.3 g).
Step 7: under nitrogen, crude a7-7 (3.3 g) and raw a7-8 (6.01 g,26.7 mmol) were dissolved in 30mL 1, 4-dioxane, and potassium acetate (2.62 g,26.7 mmol) and Pd (DPEphos) Cl were slowly added 2 (643 mg,0.9 mmol), the temperature was raised to 100℃and the reaction was stopped for 1 hour. Cooled to room temperature, filtered, washed with saturated brine, extracted with dichloromethane, dried, concentrated, and flash column chromatographed to afford intermediate a7 (2.5 g,6.2 mmol). LC-MS: [ M+H ]] + =405。
Synthesis of intermediates a14, a17
The steps are as follows: intermediate a2 (50 g,98.77 mmol) was dissolved in 750mL anhydrous DMF under nitrogen, csF (45 g,29.63 mmol) was added, and the reaction was stopped after heating to 60℃for 8 h.The reaction solution was added to 1L of water, the mixture was extracted 3 times with 750mL of ethyl acetate, the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and filtered to obtain intermediate a14 in a yield of 90%. LC-MS: [ M+H ] ] + =489。
Referring to the synthetic route for intermediate a14, the following intermediates were synthesized.
Synthesis of intermediates a15, a18
Step 1: raw material 3-methoxy-2, 2-dimethyl-3-oxomalonic acid a15-1 (1.0 g,6.8 mmol) and raw material a5-1 (850 mg,6.8 mmol) were dissolved in 20mL of anhydrous dichloromethane, EDCI (1.56 g,8.2 mmol), N-diisopropylethylamine (1.77 g,13.6 mmol) and HOBt (1.1 g,8.2 mmol) were added, and the reaction was stopped at room temperature for 16 h. To the reaction mixture was added 60mL of ice water, extracted with methylene chloride, and dried over anhydrous sodium sulfate. The mixture was separated by Flash column chromatography to give intermediate a15-2 (1.04 g,4.6 mmol) in 68% yield. LC-MS: [ M+H ]] + =218。
Step 2: intermediate a15-2 (1.04 g,4.6 mmol) was dissolved in 15mL anhydrous tetrahydrofuran at-78deg.C, and lithium aluminum hydride (350 mg,9.2 mmol) was slowly added. The reaction was stopped after heating to 0℃for 1 hour. To the reaction solution was slowly added 2mL of 10% aqueous NaOH solution to precipitate floccules, and the filtrate was concentrated under reduced pressure and flash column chromatographed to give intermediate a15 (700 mg,4.0 mmol). Yield: 87%. LC-MS: [ M+H ]] + =176。
Referring to the synthetic route for intermediate a15, the following intermediates were synthesized.
Synthesis of intermediates a19-a23
Step 1: in a 50mL reaction flask, (3S, 4R) -4-fluoro-3-hydroxypyrrolidine a19-1 (300 mg,2.86 mmol) and intermediate a19-2 (1.06 g,3.14 mmol) were added and dissolved in 5mL anhydrous THF. After stirring for 5 minutes, naBH (OAc) was added to the reaction mixture 3 (1.81 g,8.58 mmol) and 5 drops of acetic acid were reacted at room temperature for 10 hours, the reaction was stopped, the reaction solution was poured into 150mL of ice water, extracted with ethyl acetate, the organic phase was washed with saturated saline, dried over anhydrous sodium sulfate and concentrated to give 1.1g of crude intermediate a19-3 as colorless oil, LC-MS: [ M+H] + =428。
Step 2: 1.1g of the crude product of the above step, intermediate a19-3 (1.1 g), was dissolved in 15mL of anhydrous THF, 3, 4-dihydro-2H-pyran (390 mg) and p-toluenesulfonic acid (200 mg) were added, and stirred at room temperature for 1 hour, and TLC showed completion of the reaction. The reaction solution was poured into 80mL of ice water, extracted with ethyl acetate, dried over anhydrous sodium sulfate and concentrated to give 1.5g of crude intermediate a19-4, LC-MS: [ M+H ]] + =514。
Step 3: the intermediate a19-4 (1.5 g) of the above step was dissolved in 15mL of tetrahydrofuran, and tetrabutylammonium fluoride (1.5 g) was added. The reaction was allowed to react at room temperature for 3 hours, and TLC monitored the reaction was complete. The reaction solution was dissolved in 50mL of water, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and the crude product was separated by flash column chromatography (PE/ea=1/1) to give a19 (200 mg,0.73 mmol) as a colorless oil, yield: 35, LC-MS: [ M+H ]] + =274。
Referring to the synthetic route for intermediate a19, the following intermediates were synthesized.
Synthesis of intermediate a24
Step 1: at 100mLThe reaction flask was charged with starting 3, 3-difluorocyclobutan-1-amine a24-1 (1.0 g,9.34 mmol) and intermediate a19-2 (3.16 g,9.34 mmol) and 40mL of anhydrous THF was dissolved. After stirring for 5 minutes, naBH (OAc) was added to the reaction mixture 3 (2.57 g,12.34 mmol) and 10 drops of acetic acid, reacted at room temperature for 10 hours, the reaction was stopped, the reaction solution was poured into 200mL of ice water, extracted with ethyl acetate, the organic phase was washed with saturated saline, dried over anhydrous sodium sulfate, concentrated, and flash column chromatography (PE/EA, 1/1) to give 2.62g of intermediate a24-2, LC-MS: [ M+H ] as a colorless oil] + =430。
Step 2: in a 100mL reaction flask were added intermediate a24-2 (2.62 g,5.91 mmol) and aqueous formaldehyde (0.26 mL), and 40mL of tetrahydrofuran was dissolved. After stirring for 5 minutes, naBH (OAc) was added to the reaction mixture 3 (1.63 g,7.68 mmol) and 10 drops of acetic acid, reacted at room temperature for 2 hours, the reaction was stopped, the reaction solution was poured into 100mL of ice water, extracted with ethyl acetate, the organic phase was washed with saturated saline, dried over anhydrous sodium sulfate, concentrated, and flash column chromatography (PE/EA, 10/1) to give 2.0g of intermediate a24-3 as a colorless oil, LC-MS: [ M+H ]] + =444。
Step 3: the intermediate a24-3 (2.0 g,4.51 mmol) of the above step was dissolved in 20mL of tetrahydrofuran, and tetrabutylammonium fluoride (2.2 g,9.0 mmol) was added. The reaction was allowed to proceed at room temperature for 12 hours, and TLC monitored the reaction was complete. The reaction was dissolved in 50mL of water, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and the crude product was separated by flash column chromatography (DCM/MeOH, 1/1) to give a24 (800 mg,0.73 mmol) as a colorless oil, yield: 87%, LC-MS: [ M+H ] ] + =206。
Synthesis of intermediate a25
Step 1: raw material a25-1 (1.0 g,4.5 mmol) and raw material a5-1 (680 mg,5.4 mmol) were dissolved in 50mL of anhydrous dichloromethane, EDCI (1.29 g,6.75 mmol), N-diisopropylethylamine (1.74 g,13.5 mmol) and HOBt (910 mg,6.75 mmol) were added, and the reaction was stopped at room temperature for 4 hours. Adding 80mL of ice water into the reaction solution, extracting with dichloromethane, drying with anhydrous sodium sulfate, and concentrating to obtain crude productIntermediate a25-2 (1.21 g), LC-MS: [ M+H ]] + =294。
Step 2: intermediate a25-2 (1.21 g,4.13 mmol) was dissolved in 25mL anhydrous tetrahydrofuran under ice-bath, and lithium aluminum hydride (310 mg,8.3 mmol) was slowly added. The reaction was stopped after 2 hours at room temperature. To the reaction solution was slowly added 2mL of 10% aqueous NaOH solution to precipitate floccules, the filtrate was suction-filtered, concentrated under reduced pressure, and flash column chromatographed to give intermediate a25 (180 mg,0.76 mmol). Yield: 18%. LC-MS: [ M+H ]] + =238。
Synthesis of intermediate a26
Step 1: an oxetane-3, 3-diyldimethanol a26-1 (4.1 g,33.9 mmol) and triethylamine (4.11 g,40.63 mmol) were charged in a 50mL reaction flask, and 40mL of anhydrous dichloromethane was dissolved. After stirring for 5 minutes, t-butyldiphenylchlorosilane (7.18 g,33.86 mmol) was added to the reaction mixture, the reaction was stopped at room temperature for 2 hours, the reaction mixture was poured into 200mL of ice water, extracted with methylene chloride, the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated to give 12g of crude intermediate a26-2.
Step 2: the crude intermediate a26-2 (12.0 g) of the above step was dissolved in 40mL of tetrahydrofuran at-10℃and the reaction was stopped by adding pyridine sulfur trioxide (12.8 g,81.0 mmol) and reacting for 3 hours in ice bath, pouring the reaction solution into 100mL of ice water, extracting with methylene chloride, washing the organic phase with saturated brine, drying over anhydrous sodium sulfate, concentrating, separating by column chromatography to obtain intermediate a26-3 (8.0 g,22.7 mmol) in two steps of yield: 67%.
Step 3: a100 mL reaction flask was charged with the above intermediate a26-3 (8.0 g,22.7 mmol) and intermediate a5-1 (3.4 g,27.1 mmol) and 40mL anhydrous THF was dissolved. After stirring for 5 minutes, naBH (OAc) was added to the reaction mixture 3 (7.18 g,33.86 mmol) and 10 drops of acetic acid, reacting at room temperature for 10 hours, stopping the reaction, pouring the reaction solution into 200mL of ice water, extracting with ethyl acetate, washing the organic phase with saturated saline, drying with anhydrous sodium sulfate, concentrating to obtain 5.0g of crude productIntermediate a26-4, LC-MS: [ M+H ]] + =428。
Step 4: the crude product a26-4 (5.0 g,11.69 mmol) from the previous step was dissolved in 30mL of tetrahydrofuran and tetrabutylammonium fluoride (4.58 g,17.5 mmol) was added. The reaction was warmed to 40 ℃ for 12 hours and monitored by TLC to complete the reaction. The reaction was dissolved in 150mL of water, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and the crude product was separated by flash column chromatography (DCM/MeOH, 1/1) to give a colorless oil a26 (1.9 g,10.2 mmol), yield: 88%, LC-MS: [ M+H ] ] + =190。
Synthesis of intermediates a27-a28
Step 1: intermediate a1 (3.0 g,9.15 mmol) and starting 4, 7-diazaspiro [2.5 ] at room temperature]Tert-butyl octane-4-carboxylate a27-1 (2.12 g,10.1 mmol) was dissolved in 30mL of tetrahydrofuran, and N, N-diisopropylethylamine (2.3 g,17.4 mmol) was added thereto and reacted at room temperature for 8 hours. 100mL of water was added to the system, extraction was performed with methylene chloride, drying over anhydrous sodium sulfate, filtration, concentration and column chromatography were performed to obtain a pale yellow solid a27-2 (3.74 g,7.4 mmol). Yield: 81%. LC-MS: [ M+H ]] + =505。
Step 2: intermediate a27-2 (3.74 g,7.4 mmol) was dissolved in 75mL anhydrous DMF under nitrogen, csF (3.4 g,22.2 mmol) was added, and the reaction was stopped after heating to 60℃for 8 h. The reaction solution was added to 300mL of water, the mixture was extracted with ethyl acetate 3 times, the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and filtered to obtain intermediate a27 in a yield of 90%. LC-MS: [ M+H ]] + =489。
Referring to the synthetic route for intermediate a27, the following intermediates were synthesized.
Synthesis of intermediate a29
Step 1: 2-fluoro-3-methyl-4-bromopyridine a29-1 (4.5 g,23.9 mmol) was dissolved in 25mL of carbon tetrachloride, N-bromosuccinimide NBS (6.35 g,35.8 mmol) and azobisisobutyronitrile AIBN (390 mg,2.3 mmol) were slowly added and reacted at room temperature for 3 hours to stop the reaction. The reaction solution was slowly poured into 150mL of ice water, extracted with dichloromethane, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography (PE/EtOAc, 5/1) to give a29-2 (6.1 g,22.9 mmol) as an oil. Yield: 94%.
Step 2: intermediate a29-2 (5.2 g,3.7 mmol) and trimethylcyano silane TMSCN (2.9 g,5.6 mmol) were dissolved in 20mL acetonitrile, and a solution of TBAF (5.5 mmol) in tetrahydrofuran (29 mL) was added and reacted at room temperature for 16 hours to stop the reaction. The solvent was evaporated under reduced pressure and column chromatographed (PE/EtOAc, 5/1) to give a29-3 (3.4 g,15.9 mmol) as an oil. Yield: 81%.
Step 3: under ice bath, intermediate a29-3 (3.4 g,15.9 mmol) of the above step was dissolved in 20mL of DMF, naH (2.9 g,19.1 mmol) was slowly added, after stirring for 30 min, the solution became red, and a previously prepared solution of ethyl isothiocyanamide in DMF (1.8 g,15.9mmol,5 mL) was slowly added dropwise. The reaction mixture was heated to 100℃and allowed to react for 1 hour, and cooled to room temperature. The reaction was slowly poured into ice and quenched, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and the crude product was isolated by column chromatography (PE/EtOAc, 1/1) to give a29-4 (1.05 g,3.2 mmol) as a pale yellow solid. Yield: 20%. LC-MS: [ M+H ]] + =325。
Step 4: the intermediate a29-4 (1.0 g,3.1 mmol) of the above step was dissolved in 10mL of DMSO, and 10mL of aqueous sodium hydroxide (5M) was added. The reaction was stopped after 4 hours under reflux. Cooled to room temperature, the reaction was quenched by slowly adding 100mL of ice water, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and the crude product was isolated by column chromatography (PE/EtOAc, 1/1) to give a29-5 (450 mg,1.8 mmol) as a pale yellow solid. Yield: 20%. LC-MS :[M+H] + =254。
Step 5: to a mixed solution (v/v, 1/1) of the above intermediate a29-5 (450 mg,1.8 mmol) and DMAP (5 mg,0.04 mmol) in 20mL THF/DMF was added Boc anhydride (460 mg,2.16 mmol). The reaction was stopped after 12 hours at room temperature. 50mL of water was added to the system, extracted with methylene chloride, dried over anhydrous sodium sulfate, filtered, and concentrated to give crude intermediate a29-6 (760 mg).
Step 6: under nitrogen, crude a29-6 (760 mg) and starting a7-8 (560 mg,2.6 mmol) were dissolved in 10mL 1, 4-dioxane, and potassium acetate (433 mg,4.32 mmol) and Pd (DPEphos) Cl were slowly added 2 (46 mg,0.065 mmol), and the reaction was stopped after heating to 100℃for 1 hour. Cooled to room temperature, filtered, washed with saturated brine, extracted with dichloromethane, dried, concentrated, and flash column chromatographed to afford intermediate a29 (320 mg,0.82 mmol). LC-MS: [ M+H ]] + =388。
Preparation of key intermediates b1-b2
Synthesis of intermediate b1
Step 1: raw material b1-1 (10.00 g,56.8 mmol), methoxyamine hydrochloride (6.73 g,83.2 mmol) and pyridine (5.69 g,68.10 mmol) were dissolved in 10mL absolute ethanol at room temperature. The reaction solution was reacted at room temperature for 2 hours, the reaction was stopped, and concentrated under reduced pressure. The residue was dissolved in methylene chloride, and washed with dilute hydrochloric acid (2N), saturated aqueous sodium hydrogencarbonate solution, saturated brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure to give crude colorless oil b1-2 (11.30 g,55.1 mmol). LC-MS: [ M+H ] ] + =206。
Step 2: the intermediate b1-2 (1.0 g,4.9 mmol), palladium acetate (55 mg,0.24 mmol) and NBS (0.87 g,4.87 mmol) of the above step were dissolved in 10mL of anhydrous acetic acid, the reaction was stopped after the temperature of the reaction solution was raised to 80℃for 1 hour, the reaction was cooled to room temperature, the reaction solution was poured into water, filtered, and the cake was dried to give a brown solid b1-3 (1.03 g,3.6 mmol). LC-MS: [ M+H ]] + =284。
Step 3: the intermediates b1-3 of the previous step(12.5 g,43.99 mmol) was dissolved in a mixture of 60mL concentrated hydrochloric acid and 100mL 1, 4-dioxane. The reaction solution was stirred under reflux for 1 hour, the reaction was stopped, and concentrated under reduced pressure. The residue was dissolved in ethyl acetate, washed with aqueous sodium hydroxide (1N), saturated brine, dried over anhydrous sodium sulfate, concentrated, and flash column chromatographed (PE/ea=4/1) to give b1-4 (10.9 g,42.7 mmol) as a yellow solid, yield: 97%. LC-MS: [ M+H ]] + =255。
Step 4: intermediate b1-4 (7.90 g,30.97 mmol) and 1-chloromethyl-4-fluoro-1, 4-diazabicyclo [2.2.2 ] under nitrogen]Octane bis (tetrafluoroborate) (Selectfluor, 16.46g,46.5 mmol) was dissolved in 80mL methanol and 0.3mL concentrated sulfuric acid was slowly added dropwise. The reaction mixture was heated to 50℃and reacted for 5 hours, the reaction was stopped, and the mixture was concentrated under reduced pressure. The residue was dissolved in ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and flash column chromatographed (PE/ea=10/1) to give b1-5 (6.37 g,23.35 mmol) as a red solid, yield: 75%. LC-MS: [ M+H ] ] + =273。
Step 5: intermediate b1-5 (32.0 g,117.2 mmol) and pyridinium tribromide (41.22 g,128.89 mmol) were dissolved in 300mL acetonitrile under nitrogen, the reaction was stopped by heating to 60℃for 0.5 h, and the solvent was distilled off under reduced pressure. Saturated brine, ethyl acetate extraction, drying over anhydrous sodium sulfate, concentration, and flash column chromatography (PE/ea=10/1) of the crude product gave yellow solid b1-6 (36.0 g,102.3 mmol), yield: 87%. LC-MS: [ M+H ]] + =350。
Step 6: intermediate b1-6 (36.0 g,102.3 mmol) and lithium bromide (19.5 g,225 mmol) were dissolved in 100mL DMF under nitrogen, and the reaction was stopped after heating to 100deg.C for 0.5 hours. To the system was added 300mL of water, extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was isolated by flash column chromatography (PE/ea=10/1) to give b1-7 (21.0 g,77.5 mmol) as a pale yellow solid, yield: 75%. LC-MS: [ M+H ]] + =271。
Step 7: intermediate b1-7 (21.0 g,77.5 mmol) and pyridine (18.38 g,232.41 mmol) were dissolved in 200mL of dichloromethane under an ice bath and nitrogen blanket. Slowly adding the trifluoro methane sulfonic anhydride into the reaction liquid drop(26.2 g,92.96 mmol) was slowly warmed to room temperature for 1 hour, the reaction was stopped, and the solvent was distilled off under reduced pressure. The crude product was washed with saturated brine, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and separated by flash column chromatography (PE/ea=8/1) to give yellow solid b1-8 (27.50 g,68.2 mmol), yield: 88%. LC-MS: [ M+H ] ] + =403。
Step 8: intermediate b1-8 (1.0 g,2.48 mmol), zinc cyanide (146 mg,1.24 mmol), pd under nitrogen 2 (dba) 3 (114 mg,0.12 mmol) and 1,1' -bis (diphenylphosphine) ferrocene (dppf, 137mg,0.25 mmol) were dissolved in 10mL anhydrous DMF. The reaction mixture was warmed to 70℃and allowed to react for 3 hours, and cooled to room temperature. The crude product was poured into 50mL of ice water, extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated. The crude product was chromatographed on flash column (PE/ea=5/1) to give b1-9 (270 mg,0.96 mmol) as a white solid in yield: 38%. LC-MS: [ M+H ]] + =208。
Step 9: intermediate b1-9 (50 mg,0.18 mmol) was dissolved in 2mL of dichloromethane at-78℃under nitrogen, and 0.44mL of boron tribromide dichloromethane solution (concentration 2M) was slowly added dropwise. The system was slowly warmed to 0 ℃ and reacted for 16 hours, and quenched by adding 10mL of methanol. The solvent was evaporated under reduced pressure and the crude product was chromatographed on flash column (PE/ea=3/1) to give b1-10 (20 mg,0.075 mmol) as a white solid, yield: 42%. LC-MS: [ M+H ]] + =266。
Step 10: intermediate b1-10 (430 mg,26.7 mmol), pinacol biborate (823 mg,3.24 mmol), potassium acetate (477 mg,4.86 mmol), pd under nitrogen 2 (dba) 3 (74 mg,0.081 mmol) and tricyclohexylphosphine (45 mg,0.016 mmol) were dissolved in 8mL of 1, 4-dioxane, and the reaction was stopped after heating to 105℃for 10 hours. Cooled to room temperature, filtered, the system was poured into 30mL of ice water, extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated. The crude product was chromatographed on flash column (PE/ea=3/1) to give b1 (350 mg,6.2 mmol) as a pale yellow solid, yield: 69%. LC-MS: [ M+H ] ]+=314。
Synthesis of intermediate b2
Step 1: raw material 4-fluorophenylacetic acid b2-1 (50.0 g,324.4 mmol) and malonic acid cyclo (isopropylidene) ester b2-2 (51.4 g,356.8 mmol) were dissolved in 500mL acetonitrile, and 4-dimethylaminopyridine (DMAP, 3.57g,29.2 mmol) and DIEA (88.0 g,681.2 mmol) were added. After stirring for 5 minutes, pivaloyl chloride (43.0 g,356.8 mmol) was slowly added dropwise. The reaction mixture was stirred at 45℃for 3 hours, and then cooled to room temperature. The reaction solution was placed in an ice bath, and a 4N aqueous hydrochloric acid solution was added dropwise to adjust the pH to about 5, and after stirring was continued for 1 hour, the reaction solution was diluted with water, and again, the pH of the reaction solution was adjusted to about 2 with 4N hydrochloric acid, a large amount of solids were precipitated, suction filtration, washing of the cake with water, and drying to give a white solid b2-3 (104 g,371.1 mmol), and yield was quantitative. LC-MS: [ M+H ]] + =281。
Step 2: the above intermediate b2-3 (54.0 g,192.7 mmol) was slowly added to trifluoromethanesulfonic acid (228.5 g,1.5 mol). The reaction was stirred at room temperature for 2 hours and monitored by LC-MS for completion. The reaction solution was slowly poured into 500mL of ice water, and a solid was precipitated, suction-filtered, and the cake was washed with water and dried to give b2-4 (66.0 g,295.96 mmol) as a brown solid. Yield: 93%, LC-MS: [ M+H ]] + =223。
Step 3: the intermediate b2-4 (66.0 g,295.96 mmol) of the above step was dissolved in 660mL of a mixed solution of acetonitrile and water (v/1, 1/1), and the reaction was stopped after heating to 80℃for 13 hours. The solvent was distilled off under reduced pressure, washed with a saturated aqueous sodium hydrogencarbonate solution, extracted with ethyl acetate, dried over anhydrous sodium sulfate and concentrated to give a pale yellow compound b2-5 (51.8 g,291.01 mmol), yield: 97%. LC-MS: [ M+H ] ] + =179。
Step 4: under nitrogen, crude b2-5 (20.0 g,112.3 mmol), (2-bromoethynyl) triisopropylsilane (30.8 g,112.3 mmol), potassium acetate (22.0 g,224.5 mmol) and dichlorobis (4-cymene) ruthenium (II) (2.06 g,3.4 mmol) were dissolved in 200mL of 1, 4-dioxane, reacted at 100℃for 4 hours, monitored by LC-MS and filtered. The solvent was distilled off under reduced pressure, 100mL of water was added to the system, extraction was performed with ethyl acetate, drying was performed with anhydrous sodium sulfate, and concentration was performed. Separating the crude product by flash column chromatographyIsolation (PE/ea=10/1) gave b2-6 (28.0 g,78.2 mmol) as a pale yellow solid, yield: 69%. LC-MS: [ M+H ]] + =359。
Step 5: the intermediates b2-6 (28 g,78.2 mmol) and DIEA (20.19 g,156.20 mmol) were dissolved in 300mL of dichloromethane, triisopropylchlorosilane TIPSCl (18.1 g,93.7 mmol) was slowly added dropwise, the reaction solution was stirred at room temperature for 1 hour, and LC-MS monitored that the reaction was complete. The reaction solution was poured into 500mL of ice water, extracted with methylene chloride, dried over anhydrous sodium sulfate, and concentrated to give crude fuchsin oily compound b2-7.LC-MS: [ M+H ]] + =515。
Step 6: under the protection of nitrogen, crude b2-7 (58.4 g,113.43 mmol) and DIEA (51.3 g,397.0 mmol) were dissolved in 300mL of dichloromethane at-40 ℃ and trifluoromethanesulfonic anhydride (54.4 g,192.8 mmol) was slowly added dropwise, after 3 hours, stirring was continued for 0.5 hour, and the reaction was stopped. The reaction solution was poured into 500mL of ice water, extracted with methylene chloride, dried over anhydrous sodium sulfate, and concentrated. The crude product was chromatographed on flash column (PE/ea=10/1) to give compound b2-8 (57.7 g,89.2 mmol) as a pale red oil, yield: 78%. LC-MS: [ M+H ] ] + =647。
Step 7: intermediate b2-8 (61.6 g,95.2 mmol), triethylamine (38.5 g,380.9 mmol) and pinacol borane (48.7 g,380.9 mmol) were dissolved in 600mL acetonitrile under nitrogen and stirred for 5 min before adding catalyst Pd (dppf) Cl 2 (4.2 g,5.7 mmol). The reaction solution was stirred at 80℃for 4 hours and cooled to room temperature. The mixture was slowly quenched with MeOH, kept below 25 ℃ and solids precipitated. Suction filtration, meOH washing of the filter cake, drying gave compound b2 (45.9 g,73.4 mmol) as a white solid, yield: 77%. LC-MS: [ M+H ]] + =625。
Preparation of key intermediates c1-c12
Synthesis of intermediates c1-c8
Step 1: under ice bath, raw material c1-1 (20.0 g,81.5 mmol) and TEA (16.5 g,163.1 mmol) were dissolved in 250mL of methylene chloride, and the system was slowly charged withMethanesulfonic anhydride (15.6 g,89.7 mmol) was added thereto, and the reaction was stopped after the completion of the dropwise addition, and the temperature was raised to room temperature for 2 hours. 300mL of ice water is added into the system, dichloromethane extraction, anhydrous sodium sulfate drying and concentration are carried out, thus obtaining crude product c1-2, LC-MS: [ M+H ]] + =324。
Step 2: crude c1-2 (25 g,77.3 mmol) was dissolved in 300mL DMF and sodium methyl mercaptide (6.5 g,92.8 mmol) was added at room temperature and stirred for 16 hours at 90℃and the reaction stopped. The reaction solution was poured into 500mL of ice-water, extracted with ethyl acetate, washed with saturated brine, concentrated, and the crude product was separated by column chromatography to give compound c1-3 (10 g,36.4 mmol) in 47% yield. LC-MS: [ M+H ] ] + =275。
Step 3: intermediate c1-3 (16.5 g,51.0 mmol) was dissolved in 200mL anhydrous tetrahydrofuran at-78deg.C under nitrogen, LDA (12.8 g,76.6 mmol) was slowly added dropwise, and stirring was continued for 0.5 h. 1-bromo-3-chloropropane (40.2 g,255.2 mmol) was slowly added dropwise to the system, and after the completion of the dropwise addition, the reaction was continued at room temperature for 1 hour by heating, and 100mL of ice water was added to the reaction solution for quenching. Extraction with ethyl acetate, washing with saturated saline, drying with anhydrous sodium sulfate, and concentrating to obtain crude product c1-4, LC-MS: [ M+H ]] + =352。
Step 4: the crude product c1-4 obtained in the previous step was dissolved in 50mL of methylene chloride, 150mL of trifluoroacetic acid was added, and the reaction was stopped after stirring at room temperature for 1 hour. The solvent was distilled off under reduced pressure, the mixture was made weakly basic with saturated aqueous sodium hydrogencarbonate, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and the crude product was purified by column chromatography to give compounds c1-5 (2.5 g) and c1-6 (1.3 g), LC-MS: [ M+H ]] + =252。
Step 5: intermediate c1-5 (2.5 g,10.5 mmol), potassium iodide (0.17 g,1.1 mmol) and potassium carbonate (6.9 g,21.0 mmol) were dissolved in 25mL of methanol and reacted at room temperature for 16 hours to stop the reaction. 100mL of ice water was added to the system, extraction was performed with ethyl acetate, washing was performed with saturated brine, drying was performed with anhydrous sodium sulfate, and concentration was performed to obtain crude product c1-7, LC-MS: [ M+H ] ] + =216。
Step 6: the crude product c1-7 (2.1 g,9.8 mmol) was dissolved in 20mL tetrahydrofuran in ice bath, lithium aluminum hydride (750 mg,19.5 mmol) was added and stirring was continued for 1 hour, stopping the reaction. The system was quenched by adding 10mL of methanol,filtration, concentration under reduced pressure, 50mL of water was added to the mixture, extraction with methylene chloride, drying over anhydrous sodium sulfate, and concentration gave crude product c1 (directly used for the next reaction). LC-MS: [ M+H ]] + =188。
Step 7: intermediate c1-5 is replaced with c1-6 to afford intermediate c2.
Referring to the synthetic route for intermediate c1, the following intermediates were synthesized.
Synthesis of intermediate c9
Step 1: raw material c9-1 (15.0 g,71.0 mmol) was dissolved in 150mL of anhydrous tetrahydrofuran (150 mL) in an ice bath, sodium borohydride (806 mg,21.3 mmol) was slowly added, and the reaction was stopped under the ice bath for 3 hours. The solvent was distilled off under reduced pressure, 50mL of ice water was added to the mixture, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and concentrated. The crude product was isolated by column chromatography to give intermediate c9-2 (12.0 g,56.3 mmol). LC-MS: [ M+H ]] + =214。
Step 2: ice bath, intermediate c9-2 (12.0 g,56.3 mmol) and triethylamine (17.3 g,170.5 mmol) from the previous step were dissolved in 120mL of dichloromethane. After stirring for 5 minutes, a methylene chloride solution (20 mL) of methanesulfonic anhydride (14.9 g,85.2 mmol) was added dropwise thereto, and stirring was continued for 1 hour after the completion of the addition. The reaction was stopped, 200mL of ice water was added to the system, extracted with dichloromethane, and concentrated under reduced pressure to give crude product to c9-3.
Step 3: the crude c9-3 and potassium thioacetate (9.4 g,82.4 mmol) were dissolved in 150mL DMF and reacted at 60℃for 15 hours, stopping the reaction. 300mL of ice water was added to the system, extraction was performed 3 times with ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the crude product was separated by column chromatography to give intermediate c9-4 (15 g,55.4 mmol), yield in two steps: 10%. LC-MS: [ M+H ]] + =272。
Step 4: ice bath, intermediate c9-4 (15 g,55.4 mmol) from the previous step was dissolved in 300mL anhydrous tetrahydrofuran and lithium aluminum hydride (5.2 g,138 mmol) was added. After stirring for 5 minutes, the ice bath was removed and the reaction was allowed to proceed at 60℃for 2 hours. The reaction was stopped. Adding dilute hydrochloric acid into the system to quench the reaction, adjusting the pH to about 7, precipitating solid, carrying out suction filtration, and washing a filter cake with ethyl acetate to obtain an intermediate c9.LC-MS: [ M+H ]] + =174。
Synthesis of intermediate c10
The steps are as follows: intermediate c9 (2.0 g,11.5 mmol) was dissolved in 20mL DMF and NaH (920 mg,23 mmol) was added. The reaction was carried out at room temperature for 30 minutes. A solution of trifluoroiodomethane (3.4 g,17.3 mmol) in DMF (5 mL) was added to the system at-40 ℃. The reaction was stopped by slowly warming to room temperature and stirring continued for 1 hour. 50mL of ice-water was added to the reaction mixture, which was extracted with ethyl acetate, washed with saturated brine, concentrated under reduced pressure, and separated by flash column chromatography to give intermediate c10 (1.3 g,5.4 mmol) in 47% yield. LC-MS: [ M+H ] ] + =242。
Synthesis of intermediate c11
The steps are as follows: in an ice bath, intermediate c9 (2.2 g,12.7 mmol) was dissolved in 30mL DMSO and sodium hydride (1.02 g,25.9 mmol) was added. After stirring for 30 minutes, bromocyclopropane (2.3 g,19.0 mmol) was added and the reaction was stopped at room temperature for 1 hour. To the system was added 100mL of ice water, extracted with ethyl acetate, washed with saturated brine, and concentrated under reduced pressure to give intermediate c11.LC-MS: [ M+H ]] + =214。
Synthesis of intermediate c12
The steps are as follows:ice bath, intermediate c9 (1.6 g,9.2 mmol) was dissolved in 30mL DMSO and sodium hydride (378 mg,18.4 mmol) was added. After stirring for 30 minutes, bromocyclobutane (1.87 g,13.9 mmol) was added and the reaction was stopped at room temperature for 1 hour. The reaction was stopped after 1 hour at room temperature. To the system was added 100mL of ice water, extracted with ethyl acetate, washed with saturated brine, and concentrated under reduced pressure to give intermediate c12.LC-MS: [ M+H ]] + =228。
Example 2:
step 1: intermediate a3 (2.4 g,5.61 mmol) was dissolved in 50mL dioxane under nitrogen and starting material P1-1 (1.34 g,8.42 mmol) and N, N-diisopropylethylamine DIEA (1.45 g,11.2 mmol) were added. The reaction solution was stirred at 80℃for 12 hours and cooled to room temperature. 100mL of water was added to the system, extracted with ethyl acetate, dried, filtered, the solvent was distilled off under reduced pressure, and purified by column chromatography (petroleum ether: ethyl acetate=3:1) to give compound P1-2 (2.7 g,4.9 mmol). Yield: 87%, LC-MS: [ M+H ] ] + =552。
Step 2: under nitrogen, the above compound P1-2 (300 mg,0.54 mmol) and potassium phosphate (229 mg,1.08 mmol) were mixed in 6mL of anhydrous toluene, followed by the sequential addition of intermediate a7 (262 mg,0.65 mmol), xphos Pd G3 (93 mg,0.11 mmol) and Xphos (53 mg,0.11 mmol). The reaction solution was reacted at 100℃for 1 hour under nitrogen protection. The reaction was stopped, cooled to room temperature, filtered, and the solvent was distilled off under reduced pressure. The residue was chromatographed by TLC to give compound P1-3 (120 mg,0.15 mmol). Yield: 28%, LC-MS: [ M+H ]] + =807。
Step 3: p1-3 (120 mg,0.15 mmol) was dissolved in 4mL of a mixed solution of trifluoroacetic acid and dichloromethane (v/v, 1/1) under ice bath. The reaction was continued for 1 hour under nitrogen protection, and stopped. Saturated sodium bicarbonate solution was slowly added to the system and adjusted to around pH 8. Ethyl acetate extraction, evaporation of the solvent under reduced pressure and purification of the residue by preparative HPLC gave the title compound P1 (10.2 mg). LC-MS: [ M+H ]] + =607。
1 H NMR(400MHz,DMSO-d 6 )δ9.07(s,1H),8.08(s,2H),7.41(dd,J=8.4,5.3Hz,1H),7.14(dd,J=9.5,8.4Hz,1H),5.27(br,J=72Hz,1H),4.42(d,J=12.3Hz,2H),4.13(d,J=10.4Hz,1H),4.03(d,J=10.3Hz,1H),3.71–3.52(m,4H),3.13–3.06(m,2H),3.01(s,1H),2.83(q,J=8.5Hz,1H),2.35–2.27(m,1H),2.17–2.10(m,1H),2.08–1.98(m,2H),1.88–1.74(m,3H),1.65(d,J=6.6Hz,2H),1.56(d,J=7.5Hz,2H).
Referring to the synthetic route of compound P1, the following target molecule was synthesized using a similar backbone structure.
Example 3:
step 1: intermediate a2 (500 mg,0.99 mmol) was dissolved in 6mL of anhydrous DMF under nitrogen, followed by addition of starting material P1-1 (314 mg,2.0 mmol) and cesium carbonate (966 mg,2.96 mmol), and the reaction was stopped at 140℃for 2 hours under nitrogen, and cooled to room temperature. 30mL of water was added to the system, extraction was performed with ethyl acetate, and the solvent was distilled off under reduced pressure. The residue was purified by TLC chromatography (petroleum ether: ethyl acetate=1:4) to give H1-1 (110 mg,0.18 mmol) as a pale yellow solid. Yield: 18%, LC-MS: [ M+H ] ] + =630。
Step 2: h1-1 (210 mg,0.34 mmol) was dissolved in 5mL of anhydrous toluene under nitrogen, and intermediate a7 (189 mg,0.47 mmol) Pd (DPEPhos) Cl was added sequentially 2 (72 mg,0.10 mmol) and anhydrous cesium carbonate (273 mg,0.84 mmol). Under the protection of nitrogen, the reaction solution reacts for 6 hours at 105 ℃, the reaction is stopped, the reaction solution is cooled to room temperature, and the solvent is distilled off under reduced pressure. Residues ofChromatography by TLC (petroleum ether: ethyl acetate=1:2) afforded yellow solid H1-2 (80 mg,0.10 mmol). Yield: 28%, LC-MS: [ M+H ]] + =841。
Step 3: h1-2 (80 mg,0.10 mmol) was dissolved in 3mL of a mixed solution of trifluoroacetic acid and dichloromethane (v/v, 1/1) under ice bath. Under the protection of nitrogen, the reaction solution is reacted for 0.5 hour at room temperature, the reaction is stopped, saturated sodium bicarbonate solution is slowly added into the system, the pH is regulated to about 8, the ethyl acetate is used for extraction, and the concentration is reduced pressure. The residue was purified by preparative SFC (Xselect CSH C18 OBD) to give the title compound H1a (4.0 mg) and H1b (4.1 mg).
H1a: 1 H NMR(300MHz,DMSO-d 6 )δ8.23(s,1H),8.11(s,1H),7.85(s,1H),7.26(dd,J=8.4,5.3Hz,1H),7.15(dd,J=9.5,8.4Hz,1H),5.27(br,J=72Hz,1H),4.29(dd,J=20.9,12.2Hz,3H),4.14–3.91(m,2H),3.67–3.39(m,5H),3.21–2.95(m,3H),2.92–2.70(m,1H),2.14(d,J=6.8Hz,1H),2.09–1.93(m,2H),1.88–1.52(m,6H).
H1b: 1 H NMR(400MHz,DMSO-d 6 )δ8.21(s,1H),8.09(s,2H),7.84(s,1H),7.26(dd,J=8.4,5.3Hz,1H),7.18–7.11(m,1H),5.27(br,J=72Hz,1H),4.27(dd,J=19.6,12.0Hz,2H),4.08(d,J=10.3Hz,1H),3.99(d,J=10.3Hz,1H),3.49–3.55(m,3H),3.08(d,J=9.5Hz,3H),3.02(d,J=11.5Hz,2H),2.81(s,1H),2.14–2.12(m,1H),2.02(d,J=18.1Hz,2H),1.91–1.71(m,4H),1.66–1.54(m,4H).
Example 3:
step 1: in a 50mL reaction flask, intermediate a5 (420 mg,2.42 mmol) was dissolved in 10mL anhydrous THF, potassium tert-butoxide (340 mg,3.64 mmol) was added and stirred at room temperature for 30 min to give solution S1. In another 50mL reaction flask, intermediate a2 (1.0 g,2.0 mmol) was dissolved in 10mL anhydrous THF, and the prepared solution S1 was slowly added under ice bath, and stirring was continued for 1 hour, to stop the reaction. The reaction solution was poured into 100mL of ice water, extracted with ethyl acetate, and the solvent was distilled off under reduced pressure. The residue was chromatographed on flash column (petroleum ether: ethyl acetate=1:1) to give H2-1 (916 mg,1.42 mmol) as a pale yellow solid. Yield: 71%, LC-MS: [ M+H ]] + =644。
Step 2: h2-1 (480 mg,0.75 mmol) was dissolved in 10mL of anhydrous toluene under nitrogen, and intermediate a7 (414 mg,1.02 mmol), pd (DPEPhos) Cl was added sequentially 2 (22 mg,0.03 mmol) and cesium carbonate (438 mg,1.35 mmol). Under the protection of nitrogen, the reaction liquid reacts for 10 hours at 105 ℃, the reaction is stopped, the reaction liquid is cooled to room temperature, and the solvent is distilled off under reduced pressure. The residue was chromatographed by flash column chromatography (petroleum ether: ethyl acetate=1:2) to give H2-2 (450 mg,0.53 mmol) as a yellow solid. Yield: 70%, LC-MS: [ M+H ]] + =854。
Step 3: h2-2 (600 mg,0.70 mmol) was dissolved in a mixed solution of 10mL trifluoroacetic acid and dichloromethane (v/v, 1/1) under ice bath. Under the protection of nitrogen, the reaction solution is reacted for 1 hour at room temperature, the reaction is stopped, saturated sodium bicarbonate solution is slowly added into the system, the pH is regulated to about 8, the ethyl acetate is used for extraction, and the concentration is reduced pressure. The residue was chromatographed on a flash column to give H2 (320 mg,0.49 mmol) as a yellow solid, LC-MS: [ M+H ]] + =654. Yield: 70%.
H2 was purified by chiral column: unichiral CMD-5H was purified to give the target compounds H2a (peak 1) and H2b (peak 2).
Referring to the synthetic route of the compound H2a or H2b, the following target molecules were synthesized using a similar backbone structure.
Example 4:
step 1: in a 50mL reaction flask, intermediate a5 (170 mg,0.94 mmol) was dissolved in 10mL anhydrous THF, potassium tert-butoxide (180 mg,1.56 mmol) was added and stirred at room temperature for 30 min to give solution S2. In another 50mL reaction flask, intermediate a17 (400 mg,0.78 mmol) was dissolved in 10mL anhydrous THF, and the prepared solution S2 was slowly added under ice bath, stirring was continued for 1 hour, and the reaction was stopped. The reaction solution was poured into 100mL of ice water, extracted with ethyl acetate, and the solvent was distilled off under reduced pressure. The residue was purified by flash column chromatography (petroleum ether: ethyl acetate=1:1) to give H11-1 (300 mg,0.41 mmol) as a pale yellow solid. Yield: 44, LC-MS: [ M+H ]] + =734。
Step 2: h11-1 (300 mg,0.41 mmol) and CuCN (150 mg,1.64 mmol) were dissolved in 8mL anhydrous DMF under nitrogen, and the reaction was allowed to react at 100deg.C for 6 hours, cooled to room temperature, and the reaction was stopped. To the reaction solution was added 50mL of water, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and the residue was separated by flash column chromatography (petroleum ether: ethyl acetate=2:1) to give yellow solid H11-2 (110 mg,0.17 mmol). Yield: 42, LC-MS: [ M+H ] ] + =633。
Step 3: h11-2 (110 mg,0.17 mmol) was dissolved in 10mL of anhydrous toluene under nitrogen, and intermediate a7 (94 mg,0.22 mmol), pd (DPEPhos) Cl was added sequentially 2 (22 mg,0.03 mmol) and cesium carbonate (160 mg,0.48 mmol). Under the protection of nitrogen, the reaction liquid reacts for 6 hours at 110 ℃, the reaction is stopped, the reaction liquid is cooled to room temperature, and the solvent is distilled off under reduced pressure. The residue was chromatographed by flash column chromatography (petroleum ether: ethyl acetate=1:1) to give H11-3 (90 mg,0.11 mmol) as a yellow solid. Yield: 63%, LC-MS: [ M+H ]] + =845。
Step 4: h11-3 (90 mg,0.11 mmol) was dissolved in a mixed solution of 8mL trifluoroacetic acid and dichloromethane (v/v, 1/1) under ice bath. Under the protection of nitrogen, the reaction solution is reacted for 1 hour at room temperature, the reaction is stopped, saturated sodium bicarbonate solution is slowly added into the system, the pH is regulated to about 8, the ethyl acetate is used for extraction, and the concentration is reduced pressure. The residue was chromatographed on a flash column to give H11 (30 mg,0.05 mmol) as a yellow solid, LC-MS: [ M+H ]] + =645. Yield: 43%.
1 H NMR(400MHz,DMSO-d 6 )δ8.45(s,1H),8.26(s,2H),7.35(dd,J=8.4,5.2Hz,1H),7.21(t,J=8.8Hz,1H),4.58(d,J=13.6Hz,1H),4.47(d,J=12.8Hz,1H),4.34(s,2H),4.15(d,J=16.8Hz,2H),4.02(d,J=13.6Hz,2H),3.88(d,J=12.8Hz,2H),3.52-3.16(m,4H),1.96-1.83(m,6H),1.23(s,2H),0.85–0.74(m,4H).
Referring to the synthetic route of compound H11, the following target molecule was synthesized using a similar backbone structure.
example 5:
step 1: in a 50mL reaction flask, intermediate a19 (150 mg,0.55 mmol) was dissolved in 5mL anhydrous THF, potassium tert-butoxide (93 mg,0.82 mmol) was added and stirred at room temperature for 30 min to give solution S3. In another 50mL reaction flask, intermediate a2 (280 mg,0.58 mmol) was dissolved in 5mL anhydrous THF, and the prepared solution S3 was slowly added under ice bath, stirring was continued for 1 hour, and the reaction was stopped. The reaction solution was poured into 50mL of ice water, extracted with ethyl acetate, and the solvent was distilled off under reduced pressure. The residue was purified by flash column chromatography (petroleum ether: ethyl acetate=1:1) to give H13-1 (205 mg,0.28 mmol) as a pale yellow solid. Yield: 51%, LC-MS: [ M+H ] ] + =744。
Step 2: h13-1 (205 mg,0.28 mmol) was dissolved in 6mL dry toluene under nitrogen, and intermediate a7 (200 mg,0.50 mmol), pd (DPEPhos) Cl was added sequentially 2 (13 mg,0.015 mmol) and cesium carbonate (175 mg,0.54 mmol). Under the protection of nitrogen, the reaction liquid reacts for 10 hours at 105 ℃, the reaction is stopped, the reaction liquid is cooled to room temperature, and the solvent is distilled off under reduced pressure. The residue was chromatographed by flash column chromatography (petroleum ether: ethyl acetate=1:2) to give H13-2 (120 mg,0.13 mmol) as a yellow solid. Yield: 45%, LC-MS: [ M+H ]] + =955。
Step 3: h13-2 (120 mg,0.13 mmol) was dissolved in 6mL of a mixed solution of trifluoroacetic acid and dichloromethane (v/v, 1/1) under ice bath. Under the protection of nitrogen, the reaction solution is reacted for 1 hour at room temperature, the reaction is stopped, saturated sodium bicarbonate solution is slowly added into the system, the pH is regulated to about 8, the ethyl acetate is used for extraction, and the concentration is reduced pressure. The residue was chromatographed on a flash column to give H13 (32 mg) as a yellow solid, LC-MS: [ M+H ]] + =671。
1 H NMR(400MHz,DMSO-d 6 )δ8.26(s,2H),7.97(d,J=11.2Hz,1H),7.38–7.09(m,2H),5.88–5.43(m,2H),4.70–4.37(m,2H),4.29–4.00(m,6H),3.82-3.64(m,,4H),3.74–3.36(m,4H),1.93(m,4H),1.60-1.50(m,2H),1.40-1.20(m,2H).
Referring to the synthetic route of compound H13, the following target molecule was synthesized using a similar backbone structure.
example 6:
step 1: intermediate H1-1 (1.0 g,1.59 mmol) was dissolved in 12mL of methanol under nitrogen, followed by addition of sodium methoxide (102 mg,4.77 mmol), and the reaction was warmed to 60℃for 2 hours, stopped, and cooled to room temperature. 40mL of water was added to the system, extraction was performed with ethyl acetate, and the solvent was distilled off under reduced pressure. The residue was chromatographed by flash column chromatography to give P5-1 (305 mg,0.48 mmol) as a pale yellow solid. Yield: 30%, LC-MS: [ M+H ] ] + =640。
Step 2: p5-1 (305 mg,0.48 mmol) was dissolved in 5mL of anhydrous toluene under nitrogen, and intermediate a7 (270 mg,0.67 mmol), pd (DPEPhos) Cl was added sequentially 2 (90 mg,0.14 mmol) and anhydrous cesium carbonate (330 mg,0.96 mmol). Under the protection of nitrogen, the reaction solution reacts for 8 hours at 105 ℃, the reaction is stopped, the reaction solution is cooled to room temperature, and the solvent is distilled off under reduced pressure. The residue was chromatographed by column chromatography (PE/EA, 1/2) to give P5-2 (327 mg,0.38 mmol) as a yellow solid. Yield: 80%, LC-MS: [ M+H ]] + =853。
Step 3: p5-2 (327 mg,0.38 mmol) was dissolved in 4mL of a mixed solution of trifluoroacetic acid and dichloromethane (v/v, 1/1) under ice-bath. Under the protection of nitrogen, the reaction solution is reacted for 1 hour at room temperature, the reaction is stopped, saturated sodium bicarbonate solution is slowly added into the system, the pH is regulated to about 8, the ethyl acetate is used for extraction, and the concentration is reduced pressure. Residue HPurification by PLC preparative chromatography gave the title compound P5 (74 mg,0.11 mmol). Yield: 30%, LC-MS: [ M+H ]] + =653。
1 H NMR(400MHz,DMSO-d 6 )δ8.16(s,2H),7.87(d,J=0.8Hz,1H),7.29(dd,J=8.4,5.3Hz,1H),7.22–7.11(m,1H),5.68-5.54(m,1H),4.28(dt,J=35.0,17.4Hz,2H),4.06(dd,J=35.9,10.3Hz,2H),3.56(t,J=18.0Hz,4H),3.21(s,3H)3.18–3.08(m,2H),3.03(s,1H),2.90–2.76(m,1H),2.19–1.75(m,6H),1.63(dd,J=20.6,9.9Hz,4H).
Referring to the synthetic route of compound P5, the following target molecule was synthesized using a similar backbone structure.
example 7:
step 1: intermediate H2-1 (500 mg,0.78 mmol) and trifluoroethanol (156 mg,1.56 mmol) were dissolved in 10mL of tetrahydrofuran in an ice bath under nitrogen protection, then NaH (94 mg,2.34 mmol) was added, the reaction was allowed to react at room temperature for 3 hours, the reaction was stopped, and the reaction was cooled to room temperature. 30mL of water was added to the system, extraction was performed with ethyl acetate, and the solvent was distilled off under reduced pressure. The residue was chromatographed by flash column chromatography to give P7-1 (337 mg,0.47 mmol) as a pale yellow solid. Yield: 60%, LC-MS: [ M+H ] ] + =722。
Step 2: p7-1 (305 mg,0.42 mmol) was dissolved in 5mL of anhydrous toluene under nitrogen, and intermediate a7 (270 mg,0.67 mmol), pd (DPEPhos) Cl was added sequentially 2 (90 mg,0.14 mmol) and anhydrous cesium carbonate (330 mg,0.96 mmol). Under the protection of nitrogen, the reaction liquid reacts for 8 hours at 105 ℃, the reaction is stopped, and the cooling is carried outThe solvent was distilled off under reduced pressure to room temperature. The residue was chromatographed by column chromatography (PE/EA, 1/2) to give P7-2 (313 mg,0.34 mmol) as a yellow solid. Yield: 80%, LC-MS: [ M+H ]] + =934。
Step 3: p7-2 (313 mg,0.34 mmol) was dissolved in 5mL of a mixed solution of trifluoroacetic acid and dichloromethane (v/v, 1/1) under ice bath. Under the protection of nitrogen, the reaction solution is reacted for 1 hour at room temperature, the reaction is stopped, saturated sodium bicarbonate solution is slowly added into the system, the pH is regulated to about 8, the ethyl acetate is used for extraction, and the concentration is reduced pressure. The residue was purified by HPLC preparative chromatography to give the title compound P7 (82 mg,0.11 mmol). Yield: 33, LC-MS: [ M+H ]] + =734。
1 H NMR(400MHz,DMSO-d 6 )δ8.02(s,2H),7.82(s,1H),7.20(dd,J=8.3,5.4Hz,1H),7.12(t,J=8.9Hz,1H),5.24-5.10(m,1H),4.96–4.75(m,2H),4.24(dd,J=10.8,4.4Hz,2H),3.65(d,J=13.2Hz,4H),3.51(d,J=12.1Hz,2H),2.84(dd,J=23.1,10.0Hz,2H),2.72–2.58(m,1H),2.48(s,1H),2.36(dt,J=15.9,9.7Hz,2H),2.21–1.76(m,2H),1.76–1.60(m,4H),0.66–0.60(m,2H),0.46–0.41(m,2H).
Example 8:
step 1: intermediate H2-1 (500 mg,0.78 mmol) and 4-methoxybenzyl alcohol (215 mg,1.56 mmol) were dissolved in 10mL tetrahydrofuran in an ice bath under nitrogen, naH (94 mg,2.34 mmol) was then added, the reaction was allowed to react at room temperature for 3 hours, the reaction was stopped, and the reaction solution was cooled to room temperature. 30mL of water was added to the system, extraction was performed with ethyl acetate, and the solvent was distilled off under reduced pressure. The residue was chromatographed on flash column to give P8-1 (385 mg,0.51 mmol) as a pale yellow solid. Yield: 65%, LC-MS: [ M+H ] ] + =760。
Step 2: p8-1 (319 mg,0.42 mmol) was dissolved in 5mL of anhydrous toluene under nitrogen, and intermediate a7 (270 mg,0.67 mmol), pd (DPEPhos) Cl, was added sequentially 2 (90 mg,0.14 mmol) and anhydrous cesium carbonate (330 mg,0.96 mmol). Under the protection of nitrogen, the reaction liquid is at 105 DEG CThe reaction was allowed to proceed for 8 hours, the reaction was stopped, cooled to room temperature, and the solvent was distilled off under reduced pressure. The residue was chromatographed by column chromatography (PE/EA, 1/2) to give P8-2 (122 mg,0.13 mmol) as a yellow solid. Yield: 30%, LC-MS: [ M+H ]] + =972。
Step 3: p8-2 (122 mg,0.13 mmol) was dissolved in 5mL of a mixed solution of trifluoroacetic acid and dichloromethane (v/v, 1/1) under ice bath. Under the protection of nitrogen, the reaction solution is reacted for 1 hour at room temperature, the reaction is stopped, saturated sodium bicarbonate solution is slowly added into the system, the pH is regulated to about 8, the ethyl acetate is used for extraction, and the concentration is reduced pressure. The residue was purified by HPLC preparative chromatography to give the title compound P8 (19 mg,0.03 mmol). Yield: 23, LC-MS: [ M+H ]] + =653。
1 H NMR(400MHz,DMSO-d 6 )δ8.02(s,2H),7.82(s,1H),7.20(dd,J=8.3,5.4Hz,1H),7.12(t,J=8.9Hz,1H),5.32-5.18(m,1H),4.24(dd,J=10.8,4.4Hz,2H),3.65(d,J=13.2Hz,4H),3.51(d,J=12.1Hz,2H),2.84(dd,J=23.1,10.0Hz,2H),2.72–2.58(m,1H),2.48(s,1H),2.36(dt,J=15.9,9.7Hz,2H),2.21–1.76(m,2H),1.76–1.60(m,4H),0.68–0.60(m,2H),0.48–0.41(m,2H).
Example 9:
step 1: intermediate a3 (900 mg,2.1 mmol) and intermediate a5 (360 mg,2.1 mmol) were dissolved in 15mL of tetrahydrofuran in an ice bath under nitrogen, then NaH (100 mg,4.2 mmol) was added, the reaction mixture was warmed to 40℃and allowed to react for 3 hours, the reaction was stopped, and the mixture was cooled to room temperature. 30mL of water was added to the system, extraction was performed with ethyl acetate, and the solvent was distilled off under reduced pressure. The residue was chromatographed on a flash column to give P9-2 (490 mg,0.81 mmol) as a yellow solid. Yield: 38, LC-MS: [ M+H ] ] + =565。
Step 2: p9-2 (440 mg,0.78 mmol) was dissolved in a mixed solution of 6mL1, 4-dioxane and water (v/v, 5/1) under nitrogen, and starting material P9-1 (480 mg,0.94 mmol), xphos Pd G1 (180 mg,0.23 mmol) and anhydrous cesium carbonate (1.02G, 3.12 mmol) were added sequentially. Under nitrogen gasUnder the protection, the reaction solution is reacted for 3 hours at 95 ℃, the reaction is stopped, cooled to room temperature, and the solvent is distilled off under reduced pressure. The residue was chromatographed by column chromatography (PE/EA, 1/2) to give P9-3 (500 mg,0.55 mmol) as a yellow solid. Yield: 70%, LC-MS: [ M+H ]] + =915。
Step 3: intermediate P9-3 (500 mg,0.55 mmol) of the above step was dissolved in 20mL of tetrahydrofuran, and tetrabutylammonium fluoride (220 mg,0.9 mmol) was added. The reaction was allowed to proceed at room temperature for 12 hours, and TLC monitored the reaction was complete. The reaction solution was dissolved in 50mL of water, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and concentrated to give crude P9-4 (400 mg), LC-MS: [ M+H ]] + =759。
Step 4: under ice bath, crude P9-4 (400 mg,0.53 mmol) was dissolved in 5mL of a mixed solution of trifluoroacetic acid and dichloromethane (v/v, 1/1). Under the protection of nitrogen, the reaction solution is reacted for 1 hour at room temperature, the reaction is stopped, saturated sodium bicarbonate solution is slowly added into the system, the pH is regulated to about 8, the ethyl acetate is used for extraction, and the concentration is reduced pressure. The residue was purified by HPLC prep chromatography to give the title compound P9 (45 mg,0.07 mmol). Yield: 14, LC-MS: [ M+H ] ] + =615。
1 H NMR(400MHz,DMSO-d 6 )δ10.30(s,1H),9.10(s,1H),7.98(dd,J=9.2,6.0Hz,1H),7.47(t,J=9.0Hz,1H),7.41(d,J=2.4Hz,2H),7.37(s,1H),7.24(s,1H),7.22(s,2H),7.11(s,1H),4.65(d,J=13.7Hz,1H),4.49(s,1H),4.35(s,3H),4.18(s,4H),4.0-3.90(m,6H),1.97(m,7H).
Referring to the synthetic route of compound P9, the following target molecule was synthesized using a similar backbone structure.
Example 10:
step 1: in a 20mL reaction flask, intermediate a5 (142 mg,0.82 mmol) was dissolved in 5mL anhydrous THF, potassium tert-butoxide (138 mg,2.34 mmol) was added and stirred at room temperature for 30 min to give solution S4. In another 20mL reaction flask, intermediate a27 (400 mg,0.82 mmol) was dissolved in 5mL anhydrous THF, and the prepared solution S4 was slowly added under ice bath, stirring was continued for 1 hour, and the reaction was stopped. The reaction solution was poured into 100mL of ice water, extracted with ethyl acetate, and the solvent was distilled off under reduced pressure. The residue was purified by flash column chromatography (petroleum ether: ethyl acetate=1:1) to give P12-1 (420 mg,0.66 mmol) as a pale yellow solid. Yield: 80%, LC-MS: [ M+H ]] + =642。
Step 2: p12-1 (420 mg,0.66 mmol) was dissolved in 5mL of anhydrous toluene under nitrogen, and intermediate a7 (352 mg,0.87 mmol), pd (DPEPhos) Cl, was added sequentially 2 (22 mg,0.03 mmol) and cesium carbonate (438 mg,1.35 mmol). Under the protection of nitrogen, the reaction liquid reacts for 10 hours at 105 ℃, the reaction is stopped, the reaction liquid is cooled to room temperature, and the solvent is distilled off under reduced pressure. The residue was chromatographed by flash column chromatography (petroleum ether: ethyl acetate=1:2) to give yellow solid P12-2 (450 mg,0.53 mmol). Yield: 80%, LC-MS: [ M+H ] ] + =854。
Step 3: p12-2 (450 mg,0.53 mmol) was dissolved in 6mL of a mixed solution of trifluoroacetic acid and dichloromethane (v/v, 1/1) under ice bath. Under the protection of nitrogen, the reaction solution is reacted for 1 hour at room temperature, the reaction is stopped, saturated sodium bicarbonate solution is slowly added into the system, the pH is regulated to about 8, the ethyl acetate is used for extraction, and the concentration is reduced in pressure. The residue was chromatographed on a flash column to give P12 (104 mg,0.16 mmol) as a yellow solid, LC-MS: [ M+H ]] + =654. Yield: 30%.
1 H NMR(400MHz,DMSO-d 6 )δ8.15(s,2H),7.81(s,1H),7.26(dd,J=8.4,5.3Hz,1H),7.15(t,J=8.9Hz,1H),5.24–5.10(m,1H),4.22(dt,J=19.4,10.7Hz,2H),3.86–3.62(m,4H),3.01(s,2H),2.87–2.75(m,2H),2.42-2.33(m,3H),2.20–1.95(m,2H),1.91–1.75(m,1H),0.67–0.38(m,8H).
Referring to the synthetic route of compound P12, the following target molecule was synthesized using a similar backbone structure.
Example 11:
step 1: in a high-pressure reaction vessel, the raw material 4-bromo-2, 6-difluorobenzonitrile a5 (100 g,459 mmol) was dissolved in 240mL of ethanol, 400mL of aqueous ammonia was added, the reaction was allowed to proceed at 90℃for 16 hours, and the reaction was allowed to cool to room temperature, to stop the reaction. The solvent was distilled off under reduced pressure, 100mL of ice water was added to the reaction solution, extraction was performed with ethyl acetate, and the solvent was distilled off under reduced pressure. The residue was purified by flash column chromatography (petroleum ether/ethyl acetate, 9/1) to give P14-2 (74.9 g,352 mmol) as a yellow solid. Yield: 77, LC-MS: [ M+H ]] + =215。
Step 2: 2, 2-diethoxyethanol (33.8 g,252 mmol) was dissolved in 450mL anhydrous DMF under nitrogen, naH (10.08 g,252 mmol) was slowly added at 0deg.C, and after stirring for 1 hour, the last step intermediate P14-2 (45 g,210 mmol) was added. Removing ice bath, heating to 50deg.C, reacting for 2 hr, stopping reaction, cooling to room temperature, adding 1L water, extracting with ethyl acetate, and evaporating under reduced pressure to remove solvent. The residue was chromatographed by flash column chromatography (petroleum ether/ethyl acetate, 10/1) to give P14-3 (25.3 g,77.1 mmol) as a yellow solid. Yield: 37%, LC-MS: [ M+H ] ] + =329。
Step 3: 100mL of toluene was added to polyphosphoric acid (10.42 g), the temperature was raised to 100℃and the reaction was continued at that temperature for 2 hours by adding the intermediate P14-3 (10.0 g,30.4 mmol) in the previous step, and the reaction was stopped. The reaction solution was slowly poured into a large amount of ice water, extracted with ethyl acetate, and concentrated under reduced pressure. The residue was chromatographed by flash column chromatography (petroleum ether/ethyl acetate, 10/1) to give P14-4 (1.04 g,4.4 mmol) as a yellow solid, yield: 14%. LC-MS: [ M+H ]] + =236。
Step 4: intermediate the stepsThe reaction was stopped by dissolving the body P14-4 (8.3 g,35.0 mmol) in 150mL of ethanol, adding aqueous KOH (7.94 g,50 mL), and heating to 90℃for 4 hours. The organic solvent was distilled off under reduced pressure, 100mL of ice water was added to the reaction solution, extraction was performed with methylene chloride, and concentration was performed under reduced pressure. The residue was chromatographed by flash column chromatography (petroleum ether/dichloromethane, 2/1) to give P14-5 (4.0 g,15.7 mmol) as a yellow solid, yield: 45%. LC-MS: [ M+H ]] + =256。
Step 5: under nitrogen, the intermediate P14-5 (3.3 g,13.0 mmol) from the previous step was dissolved in 33mL dry THF and a tetrahydrofuran solution (20 mL) containing triphosgene (3.6 g,12.4 mmol) was slowly added dropwise at 0deg.C. The reaction was stopped after the reaction was warmed to room temperature for 2 hours, 100mL of water was added to the system, extraction was performed with ethyl acetate, and the solvent was distilled off under reduced pressure to obtain crude P14-6 (2.8 g). LC-MS: [ M+H ] ] + =282。
Step 6: under the protection of nitrogen, the crude P14-6 (2.8 g) obtained in the previous step is dissolved in 50mL phosphorus oxychloride, 5mLN, N-diisopropylethylamine is added, and the temperature is raised to 100 ℃ for reaction for 2 hours. The solvent was distilled off under reduced pressure, 100mL of water was added to the system, extracted with ethyl acetate, concentrated, and the residue was chromatographed by flash column chromatography (petroleum ether/ethyl acetate, 3/1) to give P14-7 (1.1 g,3.5 mmol) as a yellow solid, yield in two steps: 27%. LC-MS: [ M+H ]] + =319。
Step 7: intermediate P14-7 (1.0 g,3.15 mmol) and starting 3, 8-diazabicyclo [3.2.1]Tert-butyl octane-8-carboxylate a2-1 (640 mg,3.15 mmol) was dissolved in 20mL of 1, 4-dioxane, N-diisopropylethylamine (1.7 mL,9.5 mmol) was added, and the mixture was heated to 50℃and reacted for 2 hours. 60mL of water was added to the system, extraction was performed with methylene chloride, drying over anhydrous sodium sulfate, filtration, concentration and column chromatography were performed to obtain white solid P14-8 (900 mg,1.82 mmol). Yield: 58%. LC-MS: [ M+H ]] + =495。
Step 8: intermediate P14-8 (520 mg,1.05 mmol) and cesium carbonate (684 mg,2.10 mmol) were dissolved in 5mL DMF under nitrogen, intermediate a5 (803 mg,2.10 mmol) was added and the reaction was allowed to proceed at 140℃for 2 hours. Cooling to room temperature, adding 60mL of water, extracting with ethyl acetate, drying with anhydrous sodium sulfate, filtering, concentrating, and separating by column chromatography (petroleum ether/ethyl acetate, 1/1) to obtain Yellow solid P14-9 (155 mg,0.25 mmol). Yield: 23%. LC-MS: [ M+H ]] + =630。
Step 9: intermediate P14-9 (155 mg,0.25 mmol) and cesium carbonate (200 mg,0.62 mmol) were dissolved in 5mL of toluene under nitrogen, and intermediate a7 (139 mg,0.34 mmol) and Pd (DPEPhos) Cl were added 2 (52 mg,0.074 mmol) was reacted at 105℃for 3 hours. Cooled to room temperature, the system was added with 30mL of water, extracted with ethyl acetate, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography (petroleum ether/ethyl acetate, 1/4) to give P14-10 (85 mg,0.25 mmol) as a yellow solid. Yield: 41%. LC-MS: [ M+H ]] + =842。
Step 10: p14-10 (65 mg,0.077 mmol) was dissolved in 3mL of a mixed solution of trifluoroacetic acid and dichloromethane (v/v, 1/1) under ice bath. Under the protection of nitrogen, the reaction solution is reacted for 1 hour at room temperature, the reaction is stopped, saturated sodium bicarbonate solution is slowly added into the system, the pH is regulated to about 8, the ethyl acetate is used for extraction, and the concentration is reduced in pressure. The residue was chromatographed by HPLC (X Bridge Shield RP OBD column, 19X 150mm,5 μm; mobile phase A: water (10 mmol/L NH) 4 HCO 3 ) Mobile phase B is acetonitrile; flow rate: 25 mL/min) to give P14 (9.2 mg) as a white solid, LC-MS: [ M+H ]] + =642。
1 H NMR(400MHz,DMSO-d 6 )δ8.11(d,J=4.0Hz,1H),7.97(brs,2H),7.36-7.31(m,2H),7.17-7.11(m,1H),6.57(d,J=4.0Hz,1H),5.17(d,J=56.0Hz,1H),4.31-4.18(m,2H),4.07-4.03(m,1H),3.93-3.89(m,1H),3.49-3.45(m,2H),2.89-2.73(m,3H),2.41-2.27(m,3H),2.17-2.08(m,2H),1.93-1.79(m,3H),1.66-1.62(m,2H),1.32(s,1H),0.64-0.61(m,2H),0.45-0.42(m,2H).
Example 12:
step 1: intermediate c1 (330 mg,1.76 mmol) was dissolved in 1mL of anhydrous tetrahydrofuran in an ice bath, naH (85 mg,3.52 mmol) was added, and the mixture was stirred at room temperature for 0.5 hour. Intermediate a3 (350 mg,0.82 mmol) was dissolved in 1mL anhydrous tetrahydrofuran and added The reaction mixture was allowed to react at room temperature for 1 hour, and the reaction was stopped. Concentrating under reduced pressure, and separating the crude product by flash column chromatography to obtain compound P18-1 (240 mg,0.42 mmol) with a yield of 24%. LC-MS: [ M+H ]] + =579。
Step 2: under nitrogen, compound P18-1 (240 mg,0.42 mmol), intermediate b2 (270 mg,0.44 mmol), cesium carbonate (270 mg,0.83 mmol) and methanesulfonic acid [ n-butylbis (1-adamantyl) phosphine](2-amino-1, 1' -biphenyl-2-yl) palladium (Pd-G3, 10mg,0.014 mmol) was dissolved in a mixed solution of 2mL of 1, 4-dioxane and water (v/v, 5/1), and the reaction was stopped after heating to 95℃for 1 hour. The solvent was distilled off under reduced pressure, and the crude product was separated by flash column chromatography to give Compound P18-2 (300 mg,0.29 mmol) in a yield of 70%. LC-MS: [ M+H ]] + =1041。
Step 3: compound P18-2 (270 mg,0.26 mmol) and cesium fluoride (80 mg,0.52 mmol) were dissolved in 1mL DMF, and the reaction was stopped after heating to 50℃for 1 hour. 5mL of water is added into the system, extraction is carried out by ethyl acetate, drying is carried out by anhydrous sodium sulfate, and decompression concentration is carried out, thus obtaining crude P18-3.LC-MS: [ M+H ]] + =729。
Step 4: the crude product P18-3 obtained in the above step was dissolved in 1mL of 1, 4-dioxane solution of hydrogen chloride (4M concentration), reacted at room temperature for 1 hour, and a saturated aqueous sodium bicarbonate solution was slowly added to the system to adjust the pH to about 8, extracted with ethyl acetate, concentrated under reduced pressure, and purified by TLC thin layer chromatography to give Compound P18 (50 mg). LC-MS: [ M+H ] ] + =629。
1 H NMR(400MHz,DMSO-d 6 )δ10.17(s,1H),9.06(s,1H),7.99(dd,J=9.2,5.9Hz,1H),7.48(t,J=9.0Hz,1H),7.41(d,J=2.5Hz,1H),7.19(t,J=2.2Hz,1H),4.49(d,J=11.4Hz,1H),4.33(d,J=12.6Hz,1H),4.12(dd,J=10.5,3.4Hz,1H),4.02(dd,J=10.6,2.7Hz,1H),3.95(s,1H),3.69–3.53(m,4H),3.45–3.25(m,2H),2.95–2.85(m,1H),2.72–2.64(m,1H),2.57–2.52(m,1H),2.47–2.32(m,2H),2.09(s,3H),1.95–1.72(m,4H),1.90–1.60(m,4H),1.51(t,J=11.7Hz,1H).
Referring to the synthetic route of compound P18, the following target molecule was synthesized using a similar backbone structure.
Example 13:
raw material P29-1 (305 mg,2.4 mmol) and intermediate a3 (500 mg,1.98 mmol) were dissolved in 10mL of methylene chloride under ice bath, and triethylamine (301 mg,2.97 mmol) was added thereto to react at room temperature for 2 hours. To the system was added 30mL of water, extracted with dichloromethane, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to give P29-2 (650 mg,1.9 mmol) as a white solid in yield: 95%. LC-MS: [ M+H ]] + =344。
In a 50mL reaction flask, compound P29-2 (300 mg,0.87 mmol) was dissolved in 6mL anhydrous tetrahydrofuran, sodium hydride (70 mg,1.74 mmol) was added, and the mixture was stirred for 30 minutes to obtain a solution S1. Intermediate a18 was added to solution S1, and the reaction was stopped after the reaction was continued at 70 ℃ for 16 hours and cooled to room temperature. The reaction was quenched by adding 30mL of ice water, extracted with ethyl acetate, and the solvent was removed by concentrating under reduced pressure. The residue was purified by flash column chromatography (DCM/meoh=10/1) to give P29-3 (200 mg,0.40 mmol) as a white solid, yield: 46%. LC-MS: [ M+H ]] + =495。
Compound P29-3 (450 mg,0.91 mmol) and starting material P9-1 (560 mg,1.1 mmol) were dissolved in 10mL of 1, 4-dioxane and 2mL of water under nitrogen, and the catalyst XPhos Pd G2 (215 mg,0.3 mmol) and cesium carbonate (1.18G, 3.64 mmol) were added sequentially. The reaction mixture was reacted at 95℃for 2 hours, and the reaction was stopped. The solvent was removed by concentration under reduced pressure and the residue was chromatographed on flash column (DCM/meoh=20/1) to give P29-4 (500 mg,0.59 mmol) as a yellow solid. Yield: 65%, LC-MS: [ M+H ] +=845.
Compound P29-4 (200 mg,0.24 mmol) was dissolved in 4mL of tetrahydrofuran at room temperature, and tetrabutylammonium fluoride (TBAF, 130mg,0.48 mmol) was added thereto and reacted at room temperature for 1 hour. To the system was added 20mL of water, extracted with ethyl acetate, dried over anhydrous sodium sulfate, filtered, and concentrated to give crude yellow oil P29-5 (160 mg,0.23 mmol). Yield: 98%. LC-MS: [ M+H ]] + =689。
The crude P29-5 (163 mg,0.24 mmol) obtained in the above step was dissolved in 2mL of methylene chloride, and 1mL of a 1, 4-dioxane solution (4N concentration) of hydrogen chloride was added dropwise to react at room temperature for 1 hour to stop the reaction. Saturated sodium bicarbonate solution was slowly added to the system and the pH was adjusted to about 8, extracted with ethyl acetate and concentrated under reduced pressure. The residue was chromatographed on flash column to give 10mg of P29 as a yellow solid. LC-MS: [ M+H ]] + =645。
1 H NMR(400MHz,DMSO-d 6 )δ10.16(s,1H),9.34(s,1H),8.77(s,1H),8.01(dd,J=9.2,5.9Hz,1H),7.49(t,J=9.0Hz,1H),7.42(d,J=2.4Hz,1H),7.19(t,J=3.5Hz,1H),5.30–5.02(m,1H),4.54–4.41(m,2H),4.22-4.05(m,1H),4.00-3.92(m,1H),3.87-3.68(m,1H),2.85–2.60(m,5H),2.42-2.20(m,7H),2.16–1.67(m,14H).
Example 14:
the compounds were tested for KRAS G12D-mediated inhibition of p-ERK (directly reflecting the cellular level inhibitory effect of the test compounds).
The method comprises the following steps:
AGS cells cultured in F-12K medium (Gibco, cat. No. 30-2004) containing 10% fetal bovine serum and 1% penicillin were inoculated onto 384-well microplates and incubated overnight at 37℃under 5% carbon dioxide. 200. Mu.l of the compound (final concentration of dimethyl sulfoxide 0.5%) was added to each well and incubated at 37℃for 3 hours. Cells were then fixed in 8% fixative (Solarbio, cat. No. p 1112) and washed once with Phosphate Buffer (PBS). After washing, blocking solution (LI-COR, cat. No. 927-40000) was added to each well and blocked for 1 hour at room temperature. After removal of blocking solution, phospho-p44/42MAPK (T202/Y204) Rabbit mAb (CST, cat.No.97166S) and GAPDH (D4℃ 6R) Mouse mAb (CST, cat.No.4370S) antibody working solution were added to each well and incubated overnight at 4 ℃. The microwell plates were washed three times with PBS solution (PBST) containing 0.1% Tween-80, IRDye 800CW gold anti-Rabbit IgG (H+L) (LI-COR, cat. No. 926-32211) and IRDye 680RD Goat anti Mouse IgG (H+L) (LI-COR, cat. No. 926-68070) antibody working solutions were added and the microwell plates were incubated at room temperature in the absence of light. After washing the microwell plates three times using PBST, the microwell plates were centrifuged at 1000rpm for 1 min, the read plates were scanned using an Odyssey CLx (LI-COR) instrument and signal values were recorded.
IC 50 Is calculated by the formula of (2)
Calculation of compound IC using nonlinear regression equation 50 Value: y=lower plateau signal + (upper plateau signal-lower plateau signal)/(1+10 ((log ic) 50 -X) hill slope); x = log compound concentration.
Table 1: half-effective concentration inhibitory Effect of Compounds on p-ERK [ MRTX1133 as a Positive control ]
MRTX1133 structure:
example 15: inhibitory Activity of Compounds on GTP-KRAS
Diluting the test compound with 4-fold concentration gradient, transferring 0.1 μl of different concentrations of test compound to each well of 384-well microplate using ECHO (Labcyte), sequentially adding 5 μl of diluted Tag2-KRAS G12D & GTP or Tag2-KRAS WT & GTP to each well, and centrifuging at 1000RPM for 1 min; then 5. Mu.L of diluted Tag1-cRAF was added to each well, centrifuged at 1000RPM for 1 min and incubated at 25℃for 15 min; mu.L of a mixture of anti-Tag1-Tb3 and anti-Tag2-XL665 was added to each well, centrifuged at 1000RPM for 1 minute and incubated at 4℃for 3 hours; the plate was scanned at 665/615nm using Envision and signal values were recorded.
In the above analysis, the relevant detection reagents for KRAS-G12D were all derived from the commercial kit KRAS-G12D/cRAF BINDING ASSAY KITS (Cisbio, cat. No.63ADK000CB21 PEG); in KRAS-WT assays, GTP was purchased from Sigma (Cat. No. V900868), GST-cRAF was prepared by Beijing-Kaglon formation (Cat. No. 20190718), MAb Anti GST-Tb cryptate was purchased from Cisbio (Cat. No.61 GSTTLA), and other key reagents were obtained from the commercial kit KRAS-WT/SOS1 BINDING ASSAY KITS (Cisbio, cat. No.63ADK000CB15 PEH).
The calculation results were analyzed according to the following formula:
relative Ratio (RR) = (Ratio) 665/615 -Ratio Background )
Percent inhibition= [1- (RR) Compounds of formula (I) -RR Positive control well Average value)/(RR Negative control well Average value-RR Positive control well Average value of]×100
IC 50 And (3) calculating: y=lower plateau signal + (upper plateau signal-lower plateau signal)/(1+10 ≡log ic 50 -X) X hill slope). X, compound concentration log; y: percent inhibition.
The results indicate that the molecules of the invention have excellent inhibitory effect on KRAS G12D protein activation.
Example 16:
3D antiproliferative effect of compounds on KRAS G12D mutated pancreatic cancer AsPC-1 cell lines. The method comprises the following steps:
cell culture: in T75 flasks (Corning, cat. No. 430641), asPC-1 pancreatic cancer cells were cultured in RPMI 1640 medium (Hyclone, cat. No. SH 3080901B) containing 10% fetal bovine serum (Ausgreex, cat. No. FBS 500-S) and 1% green/streptomycin (Gibco, cat. No. 15140-122).
The test process comprises the following steps: diluted with nanoliter pipetting system (LABCYTE, catalog number Echo 550)The test compound is added into 384-well low adsorption cell culture plate (Labcyte, catalog number PP-0200), spread into cells, and placed at 37deg.C with 5% CO 2 Culturing in a constant temperature incubator. Test compound (1. Mu.M as initial concentration, 3-fold dilution, total 10 concentrations) was added to each well after incubation with cells for 7 daysThe 3D reagent (Promega, catalog number G9683) was read with an Envision multifunctional enzyme-labeled instrument (Perkin Elmer, catalog number Envision 2104) and the light signal was proportional to the amount of ATP in the system, while the ATP content directly characterizes the number of viable cells in the system. Finally, using XLFIT software to obtain IC of compound by using nonlinear fitting formula 50 (half inhibition concentration).
Inhibition (%) =100× (negative control mean-compound read)/(negative control mean-positive control mean)
Negative control: DMSO. Positive control: a culture medium.
Table 2: antiproliferative effect of compounds on AsPC-1 cells at half-effective concentrations
Compounds of formula (I) | IC 50 /nM |
H1a | 4.2 |
H1b | 49 |
H2b | 23 |
P4 | 851 |
P11 | 50 |
P20 | 47 |
The result shows that the molecules of the invention have good antiproliferative effect on KRAS G12D mutant tumor cell lines.
Example 17:
liver microsomal stability assay of the compounds. The method comprises the following steps:
the compound of the invention is subjected to liver microsome stability test research, the compound to be tested is incubated with liver microsomes of different species with or without NADPH, the final concentration of the compound to be tested in a test system is 1 mu M, the final concentration of NADPH is 1mM, and the final concentration of the liver microsome is 0.5mg/ml. The compound concentrations in the supernatants of the incubations at different time points over 60 minutes were measured and pharmacokinetic parameters (e.g. clearance Clint) were calculated.
The results indicate that the molecules of the invention have better metabolic stability (especially in humans).
Some molecules (e.g., H1b, H10b, P20, P24, etc.) have lower clearance and slower metabolism in humans than control MRTX 1133.
Example 18:
in vivo efficacy experiment of BALB/c nude mice. The method comprises the following steps:
colorectal cancer tumor cells GP2D mutated in KRAS G12D were cultured and inoculated into 6-8 week old female BALB/c nude mice (weighing about 20G) and all mice were inoculated subcutaneously. Mice were cultured in SPF-grade experimental environment and all mice were freely availableStandard diet for commercial certification. When the average tumor volume of the mice grows to 150mm 3 On the left and right, the test compounds were started daily intraperitoneal (ip) administration. The dosage is as follows: blank vehicle (10%Captisol in 50mM citrate buffer pH 5.0). The dose of the administration group is 10mg/kg twice daily. Tumor volumes were measured three times a week with two-dimensional calipers and animals were weighed daily. After 10 days of continuous dosing, the inhibition (TGI/100%) was calculated from the final tumor volume. The volume calculation formula is: v=1/2 a×b 2 A represents the long diameter of the tumor, and b represents the short diameter of the tumor.
Test agent | Dosage for administration | TGI |
Blank group | 0 | 0% |
MRTX1133 | 10mg/kg,BID | 186% |
P20 | 10mg/kg,BID | 187% |
The result shows that the molecule of the invention has better in vivo efficacy, can inhibit the growth of KRAS G12D mutant tumor, and has better effect than MRTX1133.
Example 19:
animal in vivo safety experiments of the compounds of the invention. The method comprises the following steps:
qualified healthy ICR mice (age 6-8 weeks, body weight 18-20 g) were selected, 3 in each group, each for single intravenous administration. A single intravenous pre-trial was performed and the dose was fuelled from 2mg/kg, with dose escalation if no mortality was seen and discontinuation if mortality occurred.
The MRTX1133 intravenous administration solution and the compound P20 intravenous administration vehicle are: DMSO/Tween 80/Solutol/physiological saline (the volume ratio of the four is 5/3/10/82), and after vortex ultrasonic treatment to dissolve the materials sufficiently, administration treatment is carried out.
Qualified healthy ICR mice (age 6-8 weeks, body weight 18-20 g) were selected, 3 in each group, each for single infusion administration. Starting with the maximum dose administered intravenously, if no death is seen, the dose is increased and if death occurs, the increase is stopped. MRTX1133 infusion dosing solution and compound P20 infusion dosing vehicle were: DMSO/Tween 80/Solutol/physiological saline (the volume ratio of the four is 5/3/10/82), and after vortex ultrasonic treatment to dissolve the materials sufficiently, administration treatment is carried out.
Compounds of formula (I) | Administration mode | Dosage for administration | Mortality rate/3 |
MRTX1133 | Infusion of inf | 4mpk | 0/3 |
MRTX1133 | Infusion of inf | 8mpk | 0/3 |
MRTX1133 | Infusion of inf | 16mpk | 0/3 |
MRTX1133 | Infusion of inf | 32mpk | 2/3 |
P20 | Infusion of inf | 16mpk | 0/3 |
P20 | Infusion of inf | 32mpk | 0/3 |
P20 | Infusion of inf | 96mpk | 0/3 |
P20 | Infusion of inf | 150mpk | 0/3 |
The results show that the molecule of the invention has better in vivo safety, and the safety is far better than MRTX1133 whether the molecule is administrated by vein or infusion.
Claims (7)
2. a pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt, enantiomer, diastereomer, solvate, hydrate, or isotopic variant thereof, and a pharmaceutically acceptable excipient; preferably, it also contains other therapeutic agents.
3. Use of a compound of claim 1, or a pharmaceutically acceptable salt, enantiomer, diastereomer, solvate, hydrate or isotopic variant thereof, for the manufacture of a medicament for the treatment and/or prophylaxis of KRAS G12D mutein mediated diseases.
4. A method of treating and/or preventing KRAS G12D mutein-mediated diseases in a subject, the method comprising administering to the subject the compound of claim 1 or a pharmaceutically acceptable salt, enantiomer, diastereomer, solvate, hydrate or isotopic variant thereof or the pharmaceutical composition of claim 2.
5. The compound of claim 1 or a pharmaceutically acceptable salt, enantiomer, diastereomer, solvate, hydrate or isotopic variant thereof or the pharmaceutical composition of claim 2 for use in the treatment and/or prevention of KRAS G12D mutein-mediated diseases.
6. The use of claim 3 or the use of the method of claim 4 or the compound or composition of claim 5, wherein the KRAS G12D mutein-mediated disease is selected from acute myeloid leukemia, juvenile cancer, childhood adrenocortical cancer, AIDS-related cancers (e.g., lymphoma and kaposi's sarcoma), anal cancer, appendiceal cancer, astrocytoma, atypical teratoid, basal cell carcinoma, cholangiocarcinoma, bladder cancer, bone cancer, brain stem glioma, brain tumor, breast cancer, bronchogenic tumor, burkitt lymphoma, carcinoid tumor, atypical teratoid, embryonic tumor, germ cell tumor, primary lymphoma, cervical cancer, childhood cancer, chordoma, cardiac tumor, chronic Lymphocytic Leukemia (CLL), chronic Myelogenous Leukemia (CML), chronic myeloproliferative disorder, colon cancer colorectal cancer, craniopharyngioma, cutaneous T-cell lymphoma, extrahepatic Ductal Carcinoma In Situ (DCIS), embryonic tumors, CNS cancers, endometrial cancer, ependymoma, esophageal cancer, olfactory neuroblastoma, ewing's sarcoma, extracranial germ cell tumor, extragonadal germ cell tumor, eye cancer, skeletal fibroblastic tumor, gall bladder cancer, gastric cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), germ cell tumor, gestational trophoblastoma, hairy cell leukemia, head and neck cancer, heart cancer, liver cancer, hodgkin's lymphoma, hypopharyngeal cancer, intraocular melanoma, islet cell tumor, pancreatic neuroendocrine tumor, renal cancer, laryngeal cancer, lip and oral cancer, liver cancer, small Leaf Carcinoma In Situ (LCIS), lung cancer, lymphoma, metastatic squamous neck cancer with suppressed primary focus, mesogenic carcinoma, oral cancer, multiple endocrine tumor syndrome, multiple myeloma/plasmacytoma, mycosis fungoides, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm, multiple myeloma, merkel cell carcinoma, malignant mesothelioma, malignant fibrous histiocytoma and osteosarcoma of the bone, nasal and sinus cancer, nasopharyngeal carcinoma, neuroblastoma, non-hodgkin's lymphoma, non-small cell lung cancer (NSCLC), oral cancer, lip and oral cancer, oropharyngeal cancer, ovarian cancer, pancreatic cancer, papilloma, paraganglioma, paranasal and nasal cancers, parathyroid cancer, penile cancer, pharyngeal cancer, pleural-pulmonary blastoma, primary Central Nervous System (CNS) lymphoma, prostate cancer, rectal cancer, transitional cell carcinoma, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, skin cancer, gastric cancer, small cell lung cancer, small intestine cancer, soft tissue sarcoma, cellular lymphoma, testicular cancer, laryngeal cancer, thymoma and thymus cancer, thyroid cancer, transitional cell carcinoma of the renal pelvis and ureter, trophoblastoma, rare childhood cancer, urinary tract cancer, uterine sarcoma, vaginal cancer, vulvar cancer, or virus-induced cancer.
7. The use of claim 3 or the method of claim 4 or the use of the compound or composition of claim 5, wherein the KRAS G12D mutein mediated disease is selected from pancreatic cancer, colorectal cancer or non-small cell lung cancer.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW111147446A TW202322797A (en) | 2021-12-09 | 2022-12-09 | Substituted bicyclic heteroaryl compound as KRAS g12d inhibitor |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2021136818 | 2021-12-09 | ||
CNPCT/CN2021/136818 | 2021-12-09 | ||
CN2022074994 | 2022-01-29 | ||
CNPCT/CN2022/074994 | 2022-01-29 | ||
CNPCT/CN2022/088988 | 2022-04-25 | ||
CN2022088988 | 2022-04-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116253748A true CN116253748A (en) | 2023-06-13 |
Family
ID=86683223
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211152921.0A Pending CN116253748A (en) | 2021-12-09 | 2022-09-21 | Substituted bicyclic heteroaryl compounds as KRAS G12D inhibitors |
CN202280040365.XA Pending CN117440953A (en) | 2021-12-09 | 2022-12-06 | Substituted bicyclic heteroaryl compounds as KRAS G12D inhibitors |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202280040365.XA Pending CN117440953A (en) | 2021-12-09 | 2022-12-06 | Substituted bicyclic heteroaryl compounds as KRAS G12D inhibitors |
Country Status (3)
Country | Link |
---|---|
CN (2) | CN116253748A (en) |
TW (1) | TW202322797A (en) |
WO (2) | WO2023103523A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023154766A1 (en) | 2022-02-09 | 2023-08-17 | Quanta Therapeutics, Inc. | Kras modulators and uses thereof |
WO2024051852A1 (en) * | 2022-09-09 | 2024-03-14 | 上海翰森生物医药科技有限公司 | Pyrimidine-containing polycyclic biological inhibitor, preparation method therefor, and use thereof |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112019024674A2 (en) * | 2017-05-25 | 2020-06-16 | Araxes Pharma Llc | COVALENT KRAS INHIBITORS |
EP4021444A4 (en) * | 2019-08-29 | 2023-01-04 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
WO2021106231A1 (en) * | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
CN115836055A (en) * | 2020-06-30 | 2023-03-21 | 益方生物科技(上海)股份有限公司 | Quinazoline compounds, preparation method and application thereof |
CN115968286A (en) * | 2020-08-26 | 2023-04-14 | 益方生物科技(上海)股份有限公司 | Heteroaryl compounds, their preparation and use |
AU2021401232A1 (en) * | 2020-12-15 | 2023-06-22 | Mirati Therapeutics, Inc. | Azaquinazoline pan-kras inhibitors |
US20240140957A1 (en) * | 2021-01-08 | 2024-05-02 | Beigene Switzerland Gmbh | Bridged compounds as kras g12d inhibitor and degrader and the use thereof |
WO2022170999A1 (en) * | 2021-02-09 | 2022-08-18 | 南京明德新药研发有限公司 | Pyridine[4,3-d]pyrimidine compound |
KR20240002245A (en) * | 2021-02-16 | 2024-01-04 | 테라스, 인크. | Compositions and methods for inhibiting RAS |
WO2022184178A1 (en) * | 2021-03-05 | 2022-09-09 | Jacobio Pharmaceuticals Co., Ltd. | Kras g12d inhibitors |
WO2022214102A1 (en) * | 2021-04-09 | 2022-10-13 | 杭州英创医药科技有限公司 | Heterocyclic compound acting as kras g12d inhibitor |
CN115304623A (en) * | 2021-04-30 | 2022-11-08 | 四川海思科制药有限公司 | Pyrimido-cyclic derivative and application thereof in medicine |
-
2022
- 2022-09-21 CN CN202211152921.0A patent/CN116253748A/en active Pending
- 2022-09-21 WO PCT/CN2022/120295 patent/WO2023103523A1/en unknown
- 2022-12-06 CN CN202280040365.XA patent/CN117440953A/en active Pending
- 2022-12-06 WO PCT/CN2022/136857 patent/WO2023104018A1/en active Application Filing
- 2022-12-09 TW TW111147446A patent/TW202322797A/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2023104018A1 (en) | 2023-06-15 |
WO2023103523A1 (en) | 2023-06-15 |
CN117440953A (en) | 2024-01-23 |
TW202322797A (en) | 2023-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2020223731B2 (en) | JAK2 and ALK2 inhibitors and methods for their use | |
CN115151532B (en) | Quinoxalindione derivatives as irreversible inhibitors of KRAS G12C muteins | |
CN116253748A (en) | Substituted bicyclic heteroaryl compounds as KRAS G12D inhibitors | |
US11168089B2 (en) | Fused pyrimidine derivatives as A2A / A2B inhibitors | |
CN114829364B (en) | Compounds that inhibit and induce degradation of EGFR kinase | |
JP7092405B2 (en) | Di (hetero) aryl macrocycle to inhibit kinase activity | |
JP2021510717A (en) | Diphenylaminopyrimidine compounds for inhibiting kinase activity | |
JP2022515335A (en) | Substituted pyrazolo [1,5-a] pyridine compound, composition containing the compound and its use | |
CA3150766A1 (en) | Triazolopyrimidines as a2a / a2b inhibitors | |
JP2021535909A (en) | Highly active STING protein agonist compound | |
CN116178347A (en) | PRMT5-MTA inhibitors | |
JP7090958B2 (en) | Highly active CSF1R inhibitor compound | |
CN116554208A (en) | Substituted bicyclic heteroaryl compounds as KRAS G12D inhibitors | |
CA3163389A1 (en) | Biphenyl derivative inhibitor, preparation method therefor and use thereof | |
CN116478136A (en) | 2-piperidinyl or 2-pyrazolyl substituted pyrimidine compounds as EGFR inhibitors | |
KR20210125024A (en) | Indoloheptamyl oxime analogs as PARP inhibitors | |
JP6985764B2 (en) | Aminopyrimidine compounds, compositions containing this compound and their use | |
CN114929707B (en) | EED inhibitor and preparation method and application thereof | |
US20210009613A1 (en) | Arylphosphine oxides for inhibiting kinase activity | |
KR20170005868A (en) | Novel compounds useful as s100-inhibitors | |
WO2022223020A1 (en) | Inhibitor targeting activated and inactivated kras g12d | |
CN116462685A (en) | Heterocyclic compound, pharmaceutical composition containing same and antitumor application of heterocyclic compound | |
CN114874189B (en) | Substituted heteroaryl derivatives, compositions and uses thereof | |
CN116783183A (en) | 1- (2- (4-cyclopropyl-1H-1, 2, 3-triazol-1-yl) acetyl) -4-hydroxy-N- (benzyl) pyrrolidine-2-carboxamide derivatives as VHL inhibitors for the treatment of anemia and cancer | |
WO2024140923A1 (en) | Prmt5-mta inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40095003 Country of ref document: HK |